Cytosolic protein-targeting engineered deubiquitinating enzymes and methods of use thereof

JP2023551068A5Inactive Publication Date: 2024-11-11FLUX THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023552148
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-06
Filing Date
2021-11-05
Publication Date
2024-11-11
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for genetic diseases associated with decreased expression or stability of cytosolic proteins, such as haploinsufficiency diseases, are limited to symptom management, with no curative options available.

Method used

Development of engineered deubiquitinating enzymes (enDubs) with a targeting moiety that specifically binds to cytosolic proteins, combined with a catalytic domain to deubiquitinate these proteins, thereby increasing their expression and stability.

Benefits of technology

The engineered fusion proteins effectively increase the levels of functional cytosolic proteins, providing a potential cure for genetic diseases by reducing ubiquitination and degradation, thus addressing the underlying cause of the disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022099033000001
    Figure 2022099033000001
  • Figure 2022099033000002
    Figure 2022099033000002
  • Figure 2022099033000003
    Figure 2022099033000003
Patent Text Reader

Abstract

Provided herein is a fusion protein comprising an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a moiety that specifically binds to a cytosolic protein. Also provided herein are methods of using the fusion protein to treat diseases, including genetic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Cross-reference of related applications This application claims the benefit of U.S. Provisional Patent Application No. 63 / 110,622, filed on November 6, 2020, under 35 U.S.C. § 119(e), the entire disclosure of which is incorporated herein by reference.

[0002] The present disclosure relates to a fusion protein comprising an effector domain comprising a catalytic domain of a deubiquitinating enzyme, or a functional fragment or variant thereof; and a targeting domain comprising a portion that specifically binds to a target cytosolic protein. The present disclosure further relates to a method of treatment using the same.

Background Art

[0003] A subset of genetic diseases is associated with a decrease in the expression level of a functional cytosolic protein or a decrease in the stability of a cytosolic protein. For example, haploinsufficient genetic diseases are caused by the presence of a single copy of a wild-type allele combined heterozygously with a loss-of-function variant allele, and the level of the expressed functional protein is insufficient to produce a standard phenotype. Haploinsufficiency can result from de novo or inherited loss-of-function mutations in the variant allele, such that little or no functional protein is produced. Despite recent advances in gene therapy, there is still no curative treatment for these diseases, and treatment typically focuses on symptom management. Thus, there is a need for new treatments for diseases associated with a decrease in the expression or stability of a functional cytosolic protein, such as genetic diseases.

Summary of the Invention

[0004] In particular, an engineered deubiquitinating enzyme (enDub) comprising a targeting moiety that specifically binds to a cytosolic target protein and a catalytic domain of the deubiquitinating enzyme is provided herein. The targeting moiety directs the catalytic domain of the deubiquitinating enzyme to the specific target cytosolic protein for deubiquitination. The fusion proteins described herein are particularly useful in methods for treating genetic disorders, especially those related to or caused by a decrease in the expression or stability of specific cytosolic proteins.

[0005] In one embodiment, a fusion protein is provided herein that comprises an effector domain containing a catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof; and a targeting domain containing a targeting moiety that specifically binds to a cytosolic protein.

[0006] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease or a metalloprotease.

[0007] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease. In some embodiments, the cysteine ​​protease is a ubiquitin-specific protease (USP), ubiquitin C-terminal hydrolase (UCH), Machado-Josephine domain protease (MJD), ovarian tumor protease (OTU), MINDY protease, or ZUFSP protease. In some embodiments, the cysteine ​​protease is a USP. In some embodiments, the USPs are USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP These are USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, or USP46.

[0008] In some embodiments, the cysteine ​​protease is UCH. In some embodiments, UCH is BAP1, UCHL1, UCHL3, or UCHL5.

[0009] In some embodiments, the cysteine ​​protease is MJD. In some embodiments, MJD is ATXN3 or ATXN3L.

[0010] In some embodiments, the cysteine ​​protease is OTU. In some embodiments, OTU is OTUB1 or OTUB2.

[0011] In some embodiments, the cysteine ​​protease is MINDY. In some embodiments, MINDY is MINDY1, MINDY2, MINDY3, or MINDY4.

[0012] In some embodiments, the cysteine ​​protease is ZUFSP. In some embodiments, ZUFSP is ZUP1.

[0013] In some embodiments, the deubiquitinating enzyme is a metalloproteinase. In some embodiments, the metalloproteinase is a Jab1 / Mov34 / Mpr1 Pad1 N-terminal + (MPN+)(JAMM) domain protease.

[0014] In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs: 1 to 112.

[0015] In some embodiments, the catalytic domain includes a catalytic domain derived from a deubiquitinating enzyme that contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs: 1 to 112.

[0016] In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences of sequence numbers 113-220 or 286.

[0017] In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 286.

[0018] In some embodiments, the catalytic domain includes an amino acid sequence that is a functional fragment of one of the amino acid sequences from SEQ ID NOs: 1 to 112.

[0019] In some embodiments, the catalytic domain includes an amino acid sequence that is a functional fragment of one of the amino acid sequences from sequence numbers 113-220 or 286.

[0020] In some embodiments, the portion that specifically binds to the cytosolic protein includes an antibody, or a functional fragment or functional variant thereof. In some embodiments, the antibody, or a functional fragment or functional variant thereof, includes a full-length antibody, a single-chain variable fragment (scFv), scFv2, scFv-Fc, Fab, Fab', F(ab')2, F(v), VHH, or (VHH)2. In some embodiments, the antibody, or a functional fragment or functional variant thereof, includes VHH or (VHH)2.

[0021] In some embodiments, the cytosolic proteins include cyclin-dependent kinase-like protein 5 (CDKL5), copper transport ATPase 2 (ATP7B), syntaxin-binding protein 1 (STXBP1), and Ras / Rap. These include GTPase-activating protein (SYNGAP1), progranulin (GRN), jagged 1 protein (JAG1), GATOR complex protein DEPDC5 (DEPDC5), tuberine (TSC2), hamartin (TSC1), kinesin-like protein KIF1A (KIF1A), dynamin-1 (DNM1), SH3 and multiple ankyrin repeat domain protein 3 (SHANK3), dystrophin (DMD), oxygen regulatory protein 1 (RP1), titin (TTN), cytoplasmic dynein 1 heavy chain 1 (DYNC1H1), TRIO and F-actin-binding protein (TRIO), high-potential ubiquitin carboxyl-terminal hydrolase FAF-X (USP9X), cystatin B (CSTB), or pterin-4-alpha-carbinolamine dehydratase (PCBD1).

[0022] In some embodiments, the cytosolic protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 221 - 328 or 287 - 289.

[0023] In some embodiments, the effector domain is directly fused to the targeting domain. In some embodiments, the effector domain is indirectly fused to the targeting domain. In some embodiments, the effector domain is indirectly fused to the targeting domain via a peptide linker. In some embodiments, the effector domain is indirectly fused to the targeting domain via a peptide linker of sufficient length such that the effector domain and the targeting domain can each bind simultaneously to their target proteins. In some embodiments, the peptide linker comprises an amino acid sequence of any one of SEQ ID NOs: 375 - 384 or 402 - 519, or an amino acid sequence of any one of SEQ ID NOs: 375 - 384 or 402 - 519 that includes one, two, or three amino acid modifications. In some embodiments, the peptide linker comprises an amino acid sequence of any one of SEQ ID NOs: 375 - 384, or an amino acid sequence of any one of SEQ ID NOs: 375 - 384 that includes one, two, or three amino acid modifications.

[0024] In some embodiments, the effector domain is operably connected to the C - terminus of the targeting domain, either directly or indirectly. In some embodiments, the effector moiety is operably connected to the N - terminus of the targeting domain, either directly or indirectly.

[0025] In some embodiments, the targeting domain comprises a VHH according to any one of claims 62 - 69, or a (VHH)2 according to any one of claims 70 - 81.

[0026] In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 286.

[0027] In some embodiments, the effector domain is indirectly fused to the targeting domain via a peptide linker that is long enough for the effector domain and the targeting domain to bind to their respective target proteins simultaneously. In some embodiments, the peptide linker comprises an amino acid sequence of any one of SEQ ID NOs: 375-384 or 402-519, or an amino acid sequence of any one of SEQ ID NOs: 375-384 or 402-519 containing one, two, or three amino acid modifications. In some embodiments, the peptide linker comprises an amino acid sequence of any one of SEQ ID NOs: 375-384, or an amino acid sequence of any one of SEQ ID NOs: 375-384 containing one, two, or three amino acid modifications.

[0028] In some embodiments, the effector domain is operably connected to the C-terminus of the targeting domain, either directly or indirectly. In some embodiments, the effector portion is operably connected to the N-terminus of the targeting domain, either directly or indirectly.

[0029] In some embodiments, the fusion protein comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 320-367.

[0030] In one embodiment, a nucleic acid molecule encoding a fusion protein described herein is provided herein. In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the nucleic acid molecule is an RNA molecule.

[0031] In one embodiment, a vector comprising a nucleic acid molecule described herein (for example, a nucleic acid molecule encoding a fusion protein described herein) is provided herein. In some embodiments, the vector is a plasmid or a viral vector.

[0032] In one embodiment, a viral particle comprising a nucleic acid molecule described herein (for example, a nucleic acid molecule encoding a fusion protein described herein) is provided herein.

[0033] In one embodiment, an in vitro cell or cell population comprising a fusion protein, a nucleic acid molecule, or a vector as described herein is provided herein.

[0034] In one embodiment, a pharmaceutical composition comprising a fusion protein, a nucleic acid, a vector, or a viral particle as described herein, and an excipient is provided herein.

[0035] In one embodiment, a method for producing a fusion protein as described herein is provided herein, comprising introducing a nucleic acid molecule, a vector, or a viral particle as described herein into in vitro cells or a population of cells; culturing the cells or a population of cells in a culture medium under conditions suitable for the expression of the fusion protein; isolating the fusion protein from the culture medium; and optionally purifying the fusion protein.

[0036] In one embodiment, a method for treating or preventing a disease in a subject is provided herein, comprising administering a fusion protein, a nucleic acid molecule, a vector, a viral particle, or a pharmaceutical composition described herein to a subject in need thereof. In some embodiments, the subject is human.

[0037] In some embodiments, the disease is associated with reduced expression of the functional version of cytosolic proteins compared to unaffected controls. In some embodiments, the disease is associated with reduced stability of the functional version of cytosolic proteins compared to unaffected controls. In some embodiments, the disease is associated with increased ubiquitination of cytosolic proteins compared to unaffected controls. In some embodiments, the disease is associated with increased ubiquitination and degradation of cytosolic proteins compared to unaffected controls. In some embodiments, the disease is a genetic disorder. In some embodiments, the disease is a haploinsufficiency disorder.

[0038] In some embodiments, the disease is SYNGAP1 encephalopathy, CDKL5 deficiency disorder, STXBP1 encephalopathy, early infantile epileptic encephalopathy type 2, Wilson's disease, early infantile epileptic encephalopathy type 4, autosomal dominant intellectual disability 5, aphasia, Aladil syndrome 1, epilepsy, tuberous sclerosis-2, tuberous sclerosis-1, KIF1A-associated neuropathy, encephalopathy, Phelan-McDermid syndrome, Becker muscular dystrophy, RP1, retinitis pigmentosa 1, dilated cardiomyopathy 1G, DYNC1H1 syndrome, TRIO-associated intellectual disability (ID), USP9X developmental disorder, progressive myoclonus epilepsy 1 (EPM1), or hyperphenylalaninemia BH4 deficiency D (HPABH4D).

[0039] In some embodiments, the target cytosolic protein is SYNGAP1 and the disease is SYNGAP1 encephalopathy; the target cytosolic protein is SYNGAP1 and the disease is autosomal dominant 5 intellectual disability; the target cytosolic protein is CDKL5 and the disease is CDKL5 deficiency disorder; the target cytosolic protein is CDKL5 and the disease is early infantile epileptic encephalopathy; the target cytosolic protein is CDKL5 and the disease is early infantile epileptic encephalopathy type 2; the target cytosolic protein is ATP7B and the disease is Wilson's disease. The target cytosolic protein is STXBP1, and the disease is STXBP1 encephalopathy; the target cytosolic protein is STXBP1, and the disease is early infantile epileptic encephalopathy; the target cytosolic protein is STXBP1, and the disease is early infantile epileptic encephalopathy type 4; the target cytosolic protein is GRN, and the disease is primary progressive aphasia and FTD (frontotemporal degeneration); the target cytosolic protein is JAG1, and the disease is Aladzil syndrome 1; the target cytosolic protein is DEPDC5, and the disease is epilepsy (for example) , familial focal 1) showing diverse foci; target cytosolic protein is TSC2 and the disease is tuberous sclerosis; target cytosolic protein is TSC2 and the disease is tuberous sclerosis type 2; target cytosolic protein is TSC2 and the disease is tuberous sclerosis type 1; target cytosolic protein is TSC1 and the disease is tuberous sclerosis; target cytosolic protein is TSC1 and the disease is tuberous sclerosis type 1; target cytosolic protein is TSC1 and the disease is tuberous sclerosis type 2; target cytosolic protein The target cytosolic protein is KIF1A, and the disease is KIF1A-associated neuropathy; the target cytosolic protein is DNM1, and the disease is DNM1 encephalopathy; the target cytosolic protein is DNM1, and the disease is encephalopathy; the target cytosolic protein is SHANK3, and the disease is Phelan-McDermid syndrome; the target cytosolic protein is DMD, and the disease is Becker muscular dystrophy; the target cytosolic protein is RP1, and the disease is retinitis pigmentosa 1; the target cytosolic protein is TTN, and the disease is dilated cardiomyopathy 1G;The target cytosolic protein is DYNC1H1, and the disease is DYNC1H1 syndrome; the target cytosolic protein is TRIO, and the disease is TRIO-associated intellectual disability (ID); the target cytosolic protein is USP9X, and the disease is USP9X developmental disorder; the target cytosolic protein is CSTB, and the disease is progressive myoclonus epilepsy 1 (EPM1); or the target cytosolic protein is PCBD1, and the disease is BH4-deficient hyperphenylalaninemia D (HPABH4D). In some embodiments, the target cytosolic protein is SYNGAP1, and the disease is SYNGAP1 encephalopathy.

[0040] In some embodiments, the fusion protein, nucleic acid molecule, vector, viral particle, or pharmaceutical composition is administered in a therapeutically effective dose. In some embodiments, the disease is a haploinsufficiency disorder. The fusion protein, nucleic acid molecule, vector, viral particle, or pharmaceutical composition is administered systemically or topically. In some embodiments, the disease is a haploinsufficiency disorder. In some embodiments, the fusion protein, nucleic acid molecule, vector, viral particle, or pharmaceutical composition is administered intravenously, subcutaneously, or intramuscularly.

[0041] In one embodiment, a fusion protein, a polynucleotide, a DNA, an RNA, a vector, a viral particle, and a pharmaceutical composition are provided herein for use as pharmaceuticals.

[0042] In one embodiment, fusion proteins, polynucleotides, DNA, RNA, vectors, viral particles, and pharmaceutical compositions described herein are provided herein for use in treating or suppressing genetic disorders.

[0043] In one embodiment, a single-chain variable domain antibody (VHH) that specifically binds to SYNGAP1 is provided herein, the VHH comprising three complementarity-determining regions: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 comprises the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, or the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, including one, two, or three amino acid modifications; and the amino acid sequence of CDR2 comprises SEQ ID NOs. 29 The amino acid sequence of sequence number 1, 295, 299, 303, 307, or 311 includes the amino acid sequence of sequence number 291, 295, 299, 303, 307, or 311, which includes one, two, or three amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of sequence number 292, 296, 300, 304, 308, or 312, which includes the amino acid sequence of sequence number 292, 296, 300, 304, 308, or 312, which includes one, two, or three amino acid modifications.

[0044] In some embodiments, the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 290, or the amino acid sequence of SEQ ID NO: 290 with one, two, or three amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 291, or the amino acid sequence of SEQ ID NO: 291 with one, two, or three amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 292, or the amino acid sequence of SEQ ID NO: 292 with one, two, or three amino acid modifications.

[0045] In some embodiments, the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 294, or the amino acid sequence of SEQ ID NO: 294 with one, two, or three amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 295, or the amino acid sequence of SEQ ID NO: 295 with one, two, or three amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 296, or the amino acid sequence of SEQ ID NO: 296 with one, two, or three amino acid modifications.

[0046] In some embodiments, the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 298, or the amino acid sequence of SEQ ID NO: 298 with one, two, or three amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 299, or the amino acid sequence of SEQ ID NO: 299 with one, two, or three amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 300, or the amino acid sequence of SEQ ID NO: 300 with one, two, or three amino acid modifications.

[0047] In some embodiments, the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 302, or the amino acid sequence of SEQ ID NO: 302 with one, two, or three amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 303, or the amino acid sequence of SEQ ID NO: 303 with one, two, or three amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 304, or the amino acid sequence of SEQ ID NO: 304 with one, two, or three amino acid modifications.

[0048] In some embodiments, the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 306, or the amino acid sequence of SEQ ID NO: 306 with one, two, or three amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 307, or the amino acid sequence of SEQ ID NO: 307 with one, two, or three amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 308, or the amino acid sequence of SEQ ID NO: 308 with one, two, or three amino acid modifications.

[0049] In some embodiments, the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 310, or the amino acid sequence of SEQ ID NO: 310 with one, two, or three amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 311, or the amino acid sequence of SEQ ID NO: 311 with one, two, or three amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 312, or the amino acid sequence of SEQ ID NO: 312 with one, two, or three amino acid modifications.

[0050] In some embodiments, VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs. 293, 297, 301, 305, 309, or 313.

[0051] In one embodiment, a nucleic acid molecule encoding a VHH as described herein is provided herein. In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the nucleic acid molecule is an RNA molecule.

[0052] In one embodiment, a vector comprising a nucleic acid molecule described herein (for example, a nucleic acid molecule encoding VHH as described herein) is provided herein. In some embodiments, the vector is a plasmid or a viral vector.

[0053] In one embodiment, a viral particle comprising a nucleic acid molecule described herein (for example, a nucleic acid molecule encoding VHH as described herein) is provided herein.

[0054] In one embodiment, an in vitro cell or cell population comprising VHH as described herein, a nucleic acid molecule as described herein (e.g., a nucleic acid molecule encoding VHH as described herein), or a vector as described herein (e.g., a vector containing a nucleic acid molecule encoding VHH as described herein) is provided herein.

[0055] In one embodiment, a pharmaceutical composition is provided herein comprising VHH as described herein, a nucleic acid molecule as described herein (for example, a nucleic acid molecule encoding VHH as described herein), or a vector as described herein (for example, a vector containing a nucleic acid molecule encoding VHH as described herein), or a viral particle as described herein (for example, a viral particle containing a nucleic acid molecule encoding VHH as described herein), and an excipient.

[0056] In one embodiment, a method for producing a VHH polypeptide as described herein is provided herein, comprising introducing a nucleic acid molecule described herein (e.g., a nucleic acid molecule encoding VHH as described herein), or a vector described herein (e.g., a vector containing a nucleic acid molecule encoding VHH as described herein), or a viral particle described herein (e.g., a viral particle containing a nucleic acid molecule encoding VHH as described herein) into in vitro cells or a population of cells; culturing the cells or a population of cells in a culture medium under conditions suitable for VHH expression; isolating VHH from the culture medium; and optionally purifying VHH.

[0057] In one embodiment, a first VHH that specifically binds to SYNGAP1, the first VHH comprising three complementarity-determining regions: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 comprises the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, or the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, which includes one, two, or three amino acid modifications; and the amino acid sequence of CDR2 comprises the amino acid sequence of SEQ ID NOs. 291, 295, 299, 303, 307, or 31 A first VHH whose CDR3 amino acid sequence includes one amino acid sequence, or the amino acid sequence of SEQ ID NOs. 291, 295, 299, 303, 307, or 311, which includes one, two, or three amino acid modifications; and / or a second VHH which specifically binds to SYNGAP1, The second VHH comprises three complementarity-determining regions: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 comprises the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, or the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, or contains one, two, or three amino acid modifications; and the amino acid sequence of CDR2 comprises the amino acid sequence of SEQ ID NOs. 291, 295, 299, 303, 307, or 311, or contains one, two, or three amino acid modifications. Provided herein is a (VHH)2 comprising the amino acid sequence of sequence numbers 291, 295, 299, 303, 307, or 311; and / or the amino acid sequence of CDR3 comprising the amino acid sequence of sequence numbers 292, 296, 300, 304, 308, or 312, or the amino acid sequence of sequence numbers 292, 296, 300, 304, 308, or 312 comprising one, two, or three amino acid modifications; the first VHH and the second VHH are operably connected directly or indirectly.

[0058] In some embodiments, the first VHH comprises three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 comprises the amino acid sequence of SEQ ID NO: 290, or the amino acid sequence of SEQ ID NO: 290 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 comprises the amino acid sequence of SEQ ID NO: 291, or the amino acid sequence of SEQ ID NO: 291 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 comprises the amino acid sequence of SEQ ID NO: 292, or the amino acid sequence of SEQ ID NO: 292 with 1, 2, or 3 amino acid modifications. The sequence includes; the second VHH includes three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 290, or the amino acid sequence of SEQ ID NO: 290 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 291, or the amino acid sequence of SEQ ID NO: 291 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 292, or the amino acid sequence of SEQ ID NO: 292 with 1, 2, or 3 amino acid modifications.

[0059] In some embodiments, the first VHH comprises three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 comprises the amino acid sequence of SEQ ID NO: 294, or the amino acid sequence of SEQ ID NO: 294 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 comprises the amino acid sequence of SEQ ID NO: 295, or the amino acid sequence of SEQ ID NO: 295 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 comprises the amino acid sequence of SEQ ID NO: 296, or the amino acid sequence of SEQ ID NO: 296 with 1, 2, or 3 amino acid modifications. The sequence includes; the second VHH includes three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 294, or the amino acid sequence of SEQ ID NO: 294 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 295, or the amino acid sequence of SEQ ID NO: 295 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 296, or the amino acid sequence of SEQ ID NO: 296 with 1, 2, or 3 amino acid modifications.

[0060] In some embodiments, the first VHH comprises three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 comprises the amino acid sequence of SEQ ID NO: 298, or the amino acid sequence of SEQ ID NO: 298 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 comprises the amino acid sequence of SEQ ID NO: 299, or the amino acid sequence of SEQ ID NO: 299 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 comprises the amino acid sequence of SEQ ID NO: 300, or the amino acid sequence of SEQ ID NO: 300 with 1, 2, or 3 amino acid modifications The sequence includes; the second VHH includes three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 298, or the amino acid sequence of SEQ ID NO: 298 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 299, or the amino acid sequence of SEQ ID NO: 299 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 300, or the amino acid sequence of SEQ ID NO: 300 with 1, 2, or 3 amino acid modifications.

[0061] In some embodiments, the first VHH comprises three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 comprises the amino acid sequence of SEQ ID NO: 302, or the amino acid sequence of SEQ ID NO: 302 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 comprises the amino acid sequence of SEQ ID NO: 303, or the amino acid sequence of SEQ ID NO: 303 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 comprises the amino acid sequence of SEQ ID NO: 304, or the amino acid sequence of SEQ ID NO: 304 with 1, 2, or 3 amino acid modifications. The sequence includes; the second VHH includes three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 302, or the amino acid sequence of SEQ ID NO: 302 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 303, or the amino acid sequence of SEQ ID NO: 303 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 304, or the amino acid sequence of SEQ ID NO: 304 with 1, 2, or 3 amino acid modifications.

[0062] In some embodiments, the first VHH comprises three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 comprises the amino acid sequence of SEQ ID NO: 306, or the amino acid sequence of SEQ ID NO: 306 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 comprises the amino acid sequence of SEQ ID NO: 307, or the amino acid sequence of SEQ ID NO: 307 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 comprises the amino acid sequence of SEQ ID NO: 308, or the amino acid sequence of SEQ ID NO: 308 with 1, 2, or 3 amino acid modifications. The sequence includes; the second VHH includes three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 306, or the amino acid sequence of SEQ ID NO: 306 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 307, or the amino acid sequence of SEQ ID NO: 307 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 308, or the amino acid sequence of SEQ ID NO: 308 with 1, 2, or 3 amino acid modifications.

[0063] In some embodiments, the first VHH comprises three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 comprises the amino acid sequence of SEQ ID NO: 310, or the amino acid sequence of SEQ ID NO: 310 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 comprises the amino acid sequence of SEQ ID NO: 311, or the amino acid sequence of SEQ ID NO: 311 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 comprises the amino acid sequence of SEQ ID NO: 312, or the amino acid sequence of SEQ ID NO: 312 with 1, 2, or 3 amino acid modifications. The sequence includes; the second VHH includes three CDRs: CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 includes the amino acid sequence of SEQ ID NO: 310, or the amino acid sequence of SEQ ID NO: 310 with 1, 2, or 3 amino acid modifications; the amino acid sequence of CDR2 includes the amino acid sequence of SEQ ID NO: 311, or the amino acid sequence of SEQ ID NO: 311 with 1, 2, or 3 amino acid modifications; and / or the amino acid sequence of CDR3 includes the amino acid sequence of SEQ ID NO: 312, or the amino acid sequence of SEQ ID NO: 312 with 1, 2, or 3 amino acid modifications.

[0064] In some embodiments, the first VHH includes an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences of sequence numbers 293, 297, 301, 305, 309, or 313; and the second VHH includes an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences of sequence numbers 293, 297, 301, 305, 309, or 313.

[0065] In some embodiments, the first VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences in SEQ ID NO: 293; the second VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences in SEQ ID NO: 293; the first VHH contains an amino acid sequence that is at least 90% identical to any one of the amino acid sequences in SEQ ID NO: 297. The first VHH contains an amino acid sequence that is 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences in Sequence ID No. 297; the second VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences in Sequence ID No. 301; The second VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences in SEQ ID NO: 301; the first VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences in SEQ ID NO: 305; the second VHH contains an amino acid sequence that is at least 90%, 91%, 9 The first VHH contains an amino acid sequence that is 2%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences in Sequence ID No. 309; the second VHH contains an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences in Sequence ID No. 309;Alternatively, the first VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences in SEQ ID NO: 313; or the second VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences in SEQ ID NO: 313.

[0066] In some embodiments, the first VHH is operably connected to the second VHH via a peptide linker.

[0067] In some embodiments, the peptide linker includes one amino acid sequence from sequence numbers 375-384 or 402-519, or one amino acid sequence from sequence numbers 375-384 or 402-519 that includes one, two, or three amino acid modifications.

[0068] In one embodiment, a nucleic acid molecule encoding (VHH)2 as described herein is provided herein. In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the nucleic acid molecule is an RNA molecule.

[0069] In one embodiment, a vector comprising a nucleic acid molecule described herein (for example, a nucleic acid molecule encoding (VHH)2 as described herein) is provided herein. In some embodiments, the vector is a plasmid or a viral vector.

[0070] In one embodiment, a viral particle comprising a nucleic acid molecule described herein (for example, a nucleic acid molecule encoding (VHH)2 as described herein) is provided herein.

[0071] In one embodiment, an in vitro cell or cell population comprising (VHH)2 as described herein, a nucleic acid molecule as described herein (for example, a nucleic acid molecule encoding (VHH)2 as described herein), or a vector as described herein (for example, a vector containing a nucleic acid molecule encoding (VHH)2 as described herein) is provided herein.

[0072] In one embodiment, a pharmaceutical composition is provided herein comprising (VHH)2 as described herein, a nucleic acid molecule as described herein (for example, a nucleic acid molecule encoding (VHH)2 as described herein), or a vector as described herein (for example, a vector containing a nucleic acid molecule encoding (VHH)2 as described herein), or a virus particle as described herein (for example, a virus particle containing a nucleic acid molecule encoding (VHH)2 as described herein), and an excipient.

[0073] In one embodiment, a method for producing the (VHH)2 polypeptide described herein is provided, comprising introducing a nucleic acid molecule described herein (e.g., a nucleic acid molecule encoding (VHH)2 described herein), or a vector described herein (e.g., a vector containing a nucleic acid molecule encoding (VHH)2 described herein), or a viral particle described herein (e.g., a viral particle containing a nucleic acid molecule encoding (VHH)2 described herein) into in vitro cells or a population of cells; culturing the cells or a population of cells in a culture medium under conditions suitable for the expression of (VHH)2, isolating (VHH)2 from the culture medium, and optionally purifying (VHH)2.

[0074] In some embodiments, the peptide linker includes one amino acid sequence from SEQ ID NOs. 375 to 384, or one amino acid sequence from SEQ ID NOs. 375 to 384 that includes one, two, or three amino acid modifications.

[0075] In one embodiment, a fusion protein is provided herein that comprises (a) an effector domain comprising a catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof; and (b) a targeting domain comprising a targeting moiety that specifically binds to a cytosolic protein.

[0076] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease or a metalloprotease.

[0077] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease. In some embodiments, the cysteine ​​protease is a ubiquitin-specific protease (USP), ubiquitin C-terminal hydrolase (UCH), Machado-Josephine domain protease (MJD), ovarian tumor protease (OTU), MINDY protease, or ZUFSP protease.

[0078] In some embodiments, the cysteine ​​protease is USP. In some embodiments, USP is USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, U The selection is made from the group consisting of SP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, and USP46.

[0079] In some embodiments, the cysteine ​​protease is UCH. In some embodiments, UCH is selected from the group consisting of BAP1, UCHL1, UCHL3, and UCHL5.

[0080] In some embodiments, the cysteine ​​protease is MJD. In some embodiments, MJD is selected from the group consisting of ATXN3 and ATXN3L.

[0081] In some embodiments, the cysteine ​​protease is OTU. In some embodiments, the OTU is selected from the group consisting of OTUB1 and OTUB2.

[0082] In some embodiments, the cysteine ​​protease is MINDY. In some embodiments, MINDY is selected from the group consisting of MINDY1, MINDY2, MINDY3, and MINDY4.

[0083] In some embodiments, the cysteine ​​protease is ZUFSP. In some embodiments, ZUFSP is ZUP1.

[0084] In some embodiments, the deubiquitinating enzyme is a metalloproteinase. In some embodiments, the metalloproteinase is a Jab1 / Mov34 / Mpr1 Pad1 N-terminal + (MPN+)(JAMM) domain protease.

[0085] In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of sequence numbers 1 to 112.

[0086] In some embodiments, the catalytic domain includes a catalytic domain derived from a deubiquitinating enzyme that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of sequence numbers 1 to 112.

[0087] In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of sequence numbers 113 to 220.

[0088] In some embodiments, the portion that specifically binds to the cytosolic protein includes an antibody, or a functional fragment or functional variant thereof. In some embodiments, the antibody, or a functional fragment or functional variant thereof, includes a full-length antibody, a single-chain variable fragment (scFv), scFv2, scFv-Fc, Fab, Fab', F(ab')2, F(v), or VHH. In some embodiments, the antibody, or a functional fragment or functional variant thereof, includes VHH.

[0089] In some embodiments, cytosolic proteins are transcription factors.

[0090] In some embodiments, the cytosolic protein is selected from the group consisting of cyclin-dependent kinase-like protein 5 (CDKL5), copper transport ATPase 2 (ATP7B), syntaxin-binding protein 1 (STXBP1), Ras / Rap GTPase-activating protein (SYNGAP1), progranulin (GRN), jagged protein 1 (JAG1), GATOR complex protein DEPDC5 (DEPDC5), tuberine (TSC2), hamartin (TSC1), kinesin-like protein KIF1A (KIF1A), dynamin-1 (DNM1), SH3 and multiple ankyrin repeat domain protein 3 (SHANK3), dystrophin (DMD), oxygen regulatory protein 1 (RP1), titin (TTN), cytoplasmic dynein 1 heavy chain 1 (DYNC1H1), TRIO and F-actin-binding protein (TRIO), and high-potential ubiquitin carboxyl-terminal hydrolase FAF-X (USP9X).

[0091] In some embodiments, the cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of sequence numbers 221-328.

[0092] In some embodiments, the effector domain is directly fused to the targeting domain. In some embodiments, the effector domain is indirectly fused to the targeting domain. In some embodiments, the effector domain is indirectly fused to the targeting domain via a peptide linker. In some embodiments, the effector domain is indirectly fused to the targeting domain via a peptide linker of sufficient length to allow the effector domain and the targeting domain to bind simultaneously to their respective target proteins.

[0093] In some embodiments, the effector domain is fused with the C-terminus of the targeting domain. In some embodiments, the effector portion is fused with the N-terminus of the targeting domain.

[0094] In one embodiment, a nucleic acid molecule encoding a fusion protein described herein is provided herein. In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the nucleic acid molecule is an RNA molecule.

[0095] In one embodiment, a vector comprising a nucleic acid molecule described herein is provided herein. In some embodiments, the vector is a plasmid or a viral vector.

[0096] In one embodiment, a virus particle containing nucleic acid as described herein is provided herein.

[0097] In one embodiment, an in vitro cell or cell population containing a fusion protein, a nucleic acid molecule, or a vector described herein is described herein.

[0098] In one embodiment, a pharmaceutical composition comprising a fusion protein, a nucleic acid molecule, a vector, or a viral particle as described herein, and an excipient is provided herein.

[0099] In one embodiment, a method for producing a fusion protein as described herein is provided, comprising (a) introducing a nucleic acid, a vector, or a viral particle as described herein into in vitro cells or a population of cells; (b) culturing the cells or a population of cells in a culture medium under conditions suitable for the expression of the fusion protein; (c) isolating the fusion protein from the culture medium; and (d) optionally purifying the fusion protein.

[0100] In one embodiment, a method for treating a disease in a subject is provided herein, comprising administering a fusion protein, nucleic acid, vector, or viral particle or pharmaceutical composition described herein to a subject in need thereof.

[0101] In some embodiments, the subject is human.

[0102] In some embodiments, the disease is associated with a decrease in the expression of the functional version of cytosolic proteins compared to unaffected controls.

[0103] In some embodiments, the disease is associated with a decrease in the stability of the functional version of cytosolic proteins compared to unaffected controls.

[0104] In some embodiments, the disease is associated with increased ubiquitination and degradation of cytosolic proteins compared to unaffected controls.

[0105] In some embodiments, the disease is a hereditary disease.

[0106] In some embodiments, the diseases include SYNGAP1 encephalopathy, CDKL5 deficiency disorder, STXBP1 encephalopathy, early infantile epileptic encephalopathy type 2, Wilson's disease, early infantile epileptic encephalopathy type 4, autosomal dominant intellectual disability 5, aphasia (e.g., primary progressive aphasia and FTD), Aladil syndrome 1, epilepsy (e.g., familial focal epilepsy), tuberous sclerosis-2, tuberous sclerosis-1, KIF1A-associated neuropathy, encephalopathy, Phelan-McDermid syndrome, Becker muscular dystrophy, RP1, retinitis pigmentosa 1, dilated cardiomyopathy 1G, DYNC1H1 syndrome, TRIO-associated intellectual disability (ID), and USP9X developmental disorder.

[0107] The method according to any one of claims 43 to 48, wherein the disorder is early infant epileptic encephalopathy type 2, Wilson's disease, early infant epileptic encephalopathy type 4, autosomal dominant intellectual disability 5, primary progressive aphasia and FTD (frontotemporal degeneration), Aladil syndrome 1, familial focal epilepsy showing diverse foci 1, tuberous sclerosis-2, tuberous sclerosis-1, KIF1A-associated neuropathy, encephalopathy, Phelan-McDermid syndrome, Becker muscular dystrophy, RP1, retinitis pigmentosa 1, dilated cardiomyopathy 1G, DYNC1H1 syndrome, TRIO-associated intellectual disability (ID), and USP9X developmental disorder.

[0108] In some embodiments, the disease is a haploinsufficiency disorder.

[0109] In some embodiments, the fusion protein is administered at a therapeutically effective dose.

[0110] In some embodiments, the fusion protein is administered systemically or topically.

[0111] In some embodiments, the fusion protein is administered intravenously, subcutaneously, or intramuscularly. [Brief explanation of the drawing]

[0112] [Figure 1]Figures 1A–1D provide schematic diagrams of exemplary fusion proteins described herein. Figure 1A is a schematic diagram of a manipulated deubiquitinase comprising a catalytic domain of a deubiquitinase and a VHH that specifically binds to a cytosolic target protein from N' to C' terminus. In this specific embodiment, the C-terminus of the VHH is directly ligated to the N-terminus of the catalytic domain of the deubiquitinase. Figure 1B is a schematic diagram of a manipulated deubiquitinase comprising a catalytic domain of a deubiquitinase that specifically binds to a cytosolic target protein from N' to C' terminus and a VHH that specifically binds to a cytosolic target protein. In this specific embodiment, the C-terminus of the catalytic domain of the deubiquitinase is directly ligated to the N-terminus of the VHH. Figure 1C is a schematic diagram of a manipulated deubiquitinase comprising a catalytic domain of a deubiquitinase and a VHH that specifically binds to a cytosolic target protein from N' to C' terminus. In this specific embodiment, the C-terminus of VHH is indirectly connected to the N-terminus of the catalytic domain of the deubiquitinase via a peptide linker. Figure 1D is a schematic diagram of a modified deubiquitinase including a catalytic domain of the deubiquitinase that specifically binds to a cytosolic target protein from the N' to the C' terminus, and VHH that specifically binds to a cytosolic target protein. In this specific embodiment, the C-terminus of the catalytic domain of the deubiquitinase is indirectly connected to the N-terminus of VHH via a peptide linker. [Figure 2] This is a schematic diagram of the assay used in Example 3 to screen the effects of targeted deubiquitination of different cytosolic proteins on target protein expression. [Figure 3] This bar graph shows the ratio of change in SHANK3 expression compared to the control (displayed). [Figure 4] This bar graph shows the ratio of change in SYNGAP1 protein expression compared to the control (shown). [Figure 5] This bar graph shows the ratio of change in PYDC2 protein expression compared to the control (a deubiquitinating enzyme without nanobodies that target the alpha-tag). [Figure 6] This bar graph shows the ratio of change in CSTB protein expression compared to the control (a deubiquitinating enzyme without nanobodies that target the alpha-tag). [Figure 7] This bar graph shows the ratio of change in PCBD1 protein expression compared to the control (a deubiquitinating enzyme without nanobodies that target alpha-tags). [Figure 8] This is an image of a reduced SDS-PAGE gel stained with Coomassie Blue. 2 μg of purified His-SynGAP-EC[1186-1277] obtained from Escherichia coli (E. coli) was loaded into the right lane. A molecular weight marker was loaded into the left lane, labeled "MW". The arrow indicates the purified His-SynGAP-EC[1186-1277] protein with a molecular weight of 15.75 kDA. [Figure 9] This bar graph shows the ratio of change in SYNGAP1 expression compared to the control group. [Modes for carrying out the invention]

[0113] 5. Detailed explanation 5.1 Overview Ubiquitination is a process mediated by ubiquitin ligases to add ubiquitin, a regulatory protein consisting of 76 amino acids, to a substrate protein. Ubiquitination generally begins with the attachment of a single ubiquitin molecule to a lysine amino acid residue on the substrate protein. The full details are incorporated herein by reference: Mevissen T. et al. Mechanisms of Deubiquitinase Specificity and Regulation Annual Review of Biochemistry 86:1, 159-192 (2017). These monoubiquitination events are abundant and perform a variety of functions. Ubiquitin itself contains seven lysine residues, all of which can be ubiquitinated to result in polyubiquitinated proteins. The full content of this work is incorporated herein by reference: Komander, D. et al. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550-563 (2009). Mono- and polyubiquitination can have multiple effects on substrate proteins, including labeling substrate proteins for proteasome-mediated degradation, altering the cellular location of proteins, altering protein activity, and / or promoting or preventing normal protein interactions. See, for example, Hershko A. et al. The ubiquitin system. Annu Rev Biochem. 67:425-79 (1998); Nandi D, et al. The ubiquitin-proteasome system. J Biosci. Mar;31(1):137-55 (2006), the full content of each is incorporated herein by reference. The effects of ubiquitination can be reversed or prevented by removing the ubiquitin protein from the substrate protein. The removal of ubiquitin from substrate proteins is mediated by deubiquitinating enzyme (DUB) proteins. (Ibid.)

[0114] Numerous genetic disorders are associated with, or caused by, a decrease in the expression level or stability of functional cytosolic proteins. For example, haploinsufficiency disorders are caused by the presence of a single copy of a wild-type allele heterozygously combined with a loss-of-function variant allele, resulting in levels of expressed functional protein that are insufficient to produce a standard phenotype. See, for example, Johnson, A. et al, Causes and effects of haploinsufficiency. Biol Rev, 94: 1774-1785 (2019), the full content of which is incorporated herein by reference. Haploinsufficiency can arise from de novo or hereditary loss-of-function mutations in the variant allele, resulting in little to no production of functional protein. Other genetic disorders result from the ubiquitination and subsequent degradation of variant but functional proteins, leading to reduced expression of functional proteins.

[0115] This disclosure provides, in particular, novel fusion proteins comprising a catalytic domain (or a functional fragment thereof) of a deubiquitinating enzyme and a targeting moiety, such as VHH, which specifically binds to a target cytosolic protein. In some embodiments, a decrease in the expression of the functional version of the target cytosolic protein or a decrease in the stability of the functional version of the target cytosolic protein is associated with a disease phenotype. Thus, the fusion proteins described herein are particularly useful for treating genetic diseases characterized by a decrease in the expression level or stability of the functional target cytosolic protein. Upon expression of the fusion protein by host cells, the catalytic domain of the deubiquitinating enzyme specifically targets and deubiquitizes the target cytosolic protein, resulting in an increase in the expression of the target cytosolic protein to a level sufficient to alleviate, for example, a disease phenotype.

[0116] 5.2 Definition The section headings used herein are for organizational purposes only and should not be considered as limiting the subject matter described.

[0117] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art in the field relating to this disclosure. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with many common dictionaries of the terms used herein.

[0118] It should be understood that the general description above and the detailed description below are merely illustrative and descriptive, and do not limit the claimed subject matter in any way. In this application, unless otherwise specifically stated, the singular use includes the plural.

[0119] It should be noted that, as used in the specification and attached claims, the singular forms "a," "an," and "the" refer to plural objects unless the context clearly indicates otherwise. Furthermore, the use of other forms of the term, such as "include," "includes," and "included," as well as "including," is not limited.

[0120] Whenever an aspect is described herein using the phrase “comprising,” it is understood that other similar aspects described by “consisting of” and / or “consisting essentially of” are also provided.

[0121] As used herein, the term "and / or" should be understood as a specific disclosure of each of two specific features or components, with or without the other. Accordingly, as used herein in phrases such as "A and / or B," the term "and / or" is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Similarly, as used in phrases such as "A, B, and / or C," the term "and / or" is intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0122] Units, prefixes, and symbols are expressed in the form adopted by the International System of Units (SI). Numerical ranges include the number defining the range. The headings provided herein are not intended to limit the various aspects of this disclosure that can be obtained by referring to the entire specification. Thus, the terms defined immediately below are better defined by referring to the entire specification.

[0123] Where described herein, any range of concentration, percentage, ratio, or integer should be understood to include, unless otherwise specified, any integer value within the range described, and, where appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer).

[0124] The terms “approximately” or “essentially composed of” refer to a value or composition that is within the acceptable margin of error for a particular value or composition as determined by a person skilled in the art, depending in part to how the value or composition was measured or determined, i.e., the limits of the measuring system. For example, “approximately” or “essentially composed of” may mean within one or more standard deviations by convention in the art. Alternatively, “approximately” or “essentially composed of” may mean a range of up to 20%. Furthermore, particularly with respect to biological systems or processes, these terms may mean a difference of up to one order of magnitude from the value or up to five times the value. Where a particular value or composition is provided in the application and claims, unless otherwise stated, the meaning of “approximately” or “essentially composed of” should be assumed to be within the acceptable margin of error for that particular value or composition.

[0125] As used herein, the term “catalytic domain” with respect to a deubiquitinating enzyme refers to an amino acid sequence of a deubiquitinating enzyme, or a variant thereof, capable of mediating the deubiquitination of a target protein. A catalytic domain may include the native amino acid sequence of a deubiquitinating enzyme, or it may include a variant amino acid sequence of a native deubiquitinating enzyme. A catalytic domain may include the smallest amino acid sequence of a deubiquitinating enzyme to mediate the deubiquitination of a target protein. A catalytic domain may include an amino acid sequence larger than the smallest amino acid sequence of a deubiquitinating enzyme to mediate the deubiquitination of a target protein.

[0126] The terms “polynucleotide” and “nucleic acid sequence” are used interchangeably herein and refer to polymers of DNA or RNA. Polynucleotide sequences are single-stranded or double-stranded; contain natural, unnatural, or modified nucleotides; and may contain natural, unnatural, or modified nucleotide-nucleotide bonds, for example, phosphoramidate or phosphorothioate bonds instead of phosphodiester bonds found between nucleotides in unmodified polynucleotide sequences. Polynucleotide sequences include, but are not limited to, all polynucleotide sequences obtained by any means available in the art, including, but not limited to, recombinant means, such as cloning of polynucleotide sequences from recombinant libraries or cell genomes, using conventional cloning techniques and polymerase chain reactions, and others, as well as by synthetic means.

[0127] The terms "amino acid sequence" and "polypeptide" are used interchangeably herein and refer to polymers of amino acids linked by one or more peptide bonds.

[0128] The term “functional variant” with respect to a protein or polypeptide, as used herein, refers to a protein that has at least one amino acid modification (e.g., substitution, deletion, or addition) compared to the amino acid sequence of a reference protein that retains at least one specific function. In some embodiments, the reference protein is the wild-type protein. For example, a functional variant of an IL-2 protein may refer to an IL-2 protein that contains amino acid substitutions compared to the wild-type IL-2 protein, which retains the ability to bind to a medium-affinity IL-2 receptor but loses the ability to bind to a high-affinity IL-2 receptor. Not all functions of the reference wild-type protein must be retained by the functional variant of the protein. In some cases, one or more functions may be selectively reduced or eliminated.

[0129] The term “functional fragment” in reference to a protein or polypeptide, as used herein, refers to a fragment of a reference protein that retains at least one specific function. For example, a functional fragment of an anti-HER2 antibody may refer to a fragment of an anti-HER2 antibody that retains the ability to specifically bind to the HER2 antigen. Not all functions of the reference protein must be retained by the functional fragment of the protein. In some cases, one or more functions may be selectively reduced or removed.

[0130] As used herein, the term “modified” in relation to a polynucleotide sequence means a polynucleotide sequence that includes at least one substitution, alteration, inversion, addition, or deletion of a nucleotide compared to a reference polynucleotide sequence. Modifications may include non-natural nucleotides. As used herein, the term “modified” in relation to an amino acid sequence means an amino acid sequence that includes at least one substitution, alteration, inversion, addition, or deletion of an amino acid residue compared to a reference amino acid sequence. Modifications may include the inclusion of non-natural amino acid residues.

[0131] As used herein, the term “derived” with respect to an amino acid sequence means an amino acid sequence having at least 80% sequence identity with a reference natural amino acid sequence. For example, a catalytic domain derived from a natural deubiquitinating enzyme means that the catalytic domain has an amino acid sequence having at least 80% sequence identity with the sequence of the deubiquitinating enzyme catalytic domain from which it is derived. As used herein, the term “derived” does not mean any particular process or method for obtaining an amino acid sequence. For example, an amino acid sequence may be chemically synthesized or recombinantly synthesized.

[0132] The term "fusion protein" and its grammatical equivalent, as used herein, refers to a protein comprising amino acid sequences derived from at least two separate proteins. The amino acid sequences of at least two separate proteins may be directly linked via peptide bonds; or they may be operably linked via amino acid linkers. Thus, the term fusion protein encompasses embodiments in which, for example, the amino acid sequence of protein A is directly linked to the amino acid sequence of protein B via peptide bonds (protein A-protein B), and embodiments in which, for example, the amino acid sequence of protein A is operably linked to the amino acid sequence of protein B via amino acid linkers (protein A-linker-protein B).

[0133] The term "fuse" and its grammatical equivalents, as used herein, refer to the operational connection of an amino acid sequence derived from one protein to an amino acid sequence derived from a different protein. The term "fuse" encompasses both direct connection via peptide bonds and indirect connection via amino acid linkers between two amino acid sequences.

[0134] "Isolated antibodies" refer to antibodies that substantially contain no other antibodies with different antigen specificities (for example, an isolated antibody that specifically binds to HER2 substantially contains no antibodies that specifically bind to antigens other than HER2). However, an isolated antibody that specifically binds to HER2 may cross-react with other antigens, such as HER2 molecules from different species. Furthermore, isolated antibodies may substantially contain no other cellular material and / or chemical substances. In comparison, "isolated" nucleic acids refer to substances with a nucleic acid composition that is significantly different, i.e., they have a distinct chemical identity, properties, and utility from nucleic acids that exist in nature. For example, unlike native DNA, isolated DNA is an independent part of native DNA, not a larger structural complex, a single part of a chromosome, found in nature. Moreover, unlike native DNA, isolated DNA can, among other things, be used as PCR primers or hybridization probes to measure gene expression to diagnose diseases or predict the effectiveness of therapeutic drugs, and to detect biomarker genes or mutations. Isolated nucleic acids can also be purified using standard techniques well known in the art so as to be substantially free of other cellular components or other contaminants, such as nucleic acids or proteins from other cells.

[0135] As used herein, the term “antibody” is used in its broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments (i.e., antigen-binding fragments as defined herein) insofar as they exhibit the desired antigen-binding activity. Therefore, the term “antibody” includes, for example, full-length antibodies, antigen-binding fragments of full-length antibodies, antibody CDRs, molecules containing VH and / or VL regions; and antibody-like scaffolds (e.g., fibronectin). Examples of antibodies include monoclonal antibodies, recombinant antibodies, monospecific antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetramer antibodies containing two heavy chains and two light chain molecules, antibody light chain monomers, antibody heavy chain monomers, antibody light chain dimers, antibody heavy chain dimers, antibody light chain-antibody heavy chain pairs, intrabodies, heteroconjugate antibodies, antibody-drug conjugates, single-domain antibodies (e.g., VHH, (VHH)2), monovalent antibodies, single-chain antibodies, single-chain Fv(scFv;(scFv)2), camelized antibodies, affybodies, Fab fragments (e.g., Fab, single-chain Fab(scFab), F(ab')2 fragment, disulfide-linked Fv(sdFv), anti-idiotype (anti-Id) antibodies (e.g., anti-anti-Id antibodies) The antibodies described herein include, but are not limited to, diabodies, tribodies, and antibody-like scaffolds (e.g., fibronectin), Fc fusions (e.g., Fab-Fc, scFv-Fc, VHH-Fc, (scFv)2-Fc, (VHH)2-Fc, and any of the antigen-binding fragments described above), and conjugates or fusion proteins containing any of the above. In certain embodiments, the antibodies described herein refer to a population of polyclonal antibodies. In certain embodiments, the antibodies described herein refer to a population of monoclonal antibodies. Antibodies can be any type (e.g., IgG, IgE, IgM, IgD, IgA or IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 or IgA2), or any subclass (e.g., IgG 2a Or IgG2b ) may be an immunoglobulin (Ig) molecule. In certain embodiments, the antibody described herein is an IgG antibody, or a class thereof (e.g., human IgG1 or IgG4) or a subclass thereof. In specific embodiments, the antibody is a humanized monoclonal antibody. In other specific embodiments, the antibody is a human monoclonal antibody.

[0136] The term "full-length antibody," as used herein, refers to an antibody having a structure substantially similar to a native antibody structure, comprising two heavy chains and two light chains interconnected by disulfide bonds. In some embodiments, the two heavy chains contain substantially identical amino acid sequences; the two light chains contain substantially identical amino acid sequences. While antibody chains may be substantially identical, they are not entirely identical if they differ due to post-translational modifications such as C-terminal cleavage of lysine residues or selective glycosylation patterns.

[0137] The terms “antigen-binding fragment” and “antigen-binding domain” are used interchangeably herein and refer to one or more polypeptides other than a full-length antibody, which are capable of specifically binding to an antigen and include a portion of a full-length antibody (e.g., VH, VL). Exemplary antigen-binding fragments include, but are not limited to, single-domain antibodies (e.g., VHH, (VHH)2), single-chain antibodies, single-chain Fv(scFv;(scFv)2), camelized antibodies, aphibodies, Fab fragments (e.g., Fab, single-chain Fab(scFab), F(ab')2 fragment, and disulfide-linked Fv(sdFv)). The antigen-binding domain may be a portion of a larger protein, such as a full-length antibody.

[0138] The term "(scFv)2," as used herein, refers to an antibody comprising first and second scFvs operably linked (e.g., via a linker). The first and second scFvs can specifically bind to the same or different antigens. In some embodiments, the first and second scFvs are operably linked by amino acids via an amino acid linker.

[0139] The term "(VHH)2," as used herein, refers to an antibody comprising first and second VHHs operably linked (e.g., via a linker). The first and second VHHs can specifically bind to the same or different antigens. In some embodiments, the first and second VHHs are operably linked by amino acids via an amino acid linker.

[0140] As used herein, the term "Fab-Fc" refers to an antibody comprising a Fab operably linked to an Fc domain or a subunit of an Fc domain. The full-length antibodies described herein comprise two Fabs, one of which is operably linked to one Fc domain and the other Fab is operably linked to a second Fc domain.

[0141] As used herein, the term "scFv-Fc" refers to an antibody comprising an Fc domain or an scFv operably linked to a subunit of an Fc domain.

[0142] As used herein, the term "VHH-Fc" refers to an antibody comprising a VHH domain or a subunit of an Fc domain operably linked to it.

[0143] When used herein, the term "(scFv)2-Fc" refers to (scFv)2 operably coupled with an Fc domain or a subunit of an Fc domain.

[0144] When used herein, the term "(VHH)2-Fc" refers to (VHH)2 operably coupled with an Fc domain or a subunit of an Fc domain.

[0145] "Antibody-like scaffolds" are well known in this art, and for example, fibronectin and engineered ankyrin repeat proteins (DARPin) have been used as scaffolds in place of antigen-binding domains. See, for example, Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255 (2009) and Stumpp et al., Darpins: A new generation of protein therapeutics. Drug Discovery Today 13: 695-701 (2008). Exemplary antibody-like scaffold proteins include, but are not limited to, lipocalin (Anticalin), protein A-derived molecules such as the Z domain (afibody), A domain (avimer / maxibody) of protein A, and serum transferrin (trans-body); engineered ankyrin repeat protein (DARPin), VNAR fragments, fibronectin (AdNectin), and C-type lectin domains (Tetranectin); variable domains (VNAR fragments) of novel antigen receptor beta-lactamases, human gamma-crystallin or ubiquitin (afirin molecules); Knitz-type domains of human protease inhibitors, microbodies of proteins from the Notchin family, peptide aptamers, and fibronectin (AdNectin).

[0146] As used herein, the terms “CDR” or “complementarity-determining region” mean discontinuous antigen-binding sites found within the variable regions of both heavy-chain and light-chain polypeptides. These particular regions are described by Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et al., Sequences of protein of immunological interest. (1991), all of which are incorporated herein by reference in their entirety. Unless otherwise specified, the term “CDR” is a CDR as defined by Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et al., Sequences of protein of immunological interest. (1991).

[0147] As used herein, the term “framework (FR) amino acid residue” refers to an amino acid within the framework region of the antibody variable region. The terms “framework region” or “FR region” as used herein include amino acid residues that are part of the variable region but not part of the CDR (e.g., using the Kabat definition of CDR).

[0148] As used herein, the term “heavy chain” may refer to any distinct type, for example, any subclass of IgG based on the amino acid sequence of the constant domain, such as IgG1, IgG2, IgG3, and IgG4, which give rise to antibodies of the IgA, IgD, IgE, IgG, and IgM classes, respectively, including alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ).

[0149] As used herein, the term “light chain” may, when used in reference to antibodies, refer to any distinct type, for example, kappa (κ) or lambda (λ) based on the amino acid sequence of the constant domain. Light chain amino acid sequences are well known in the art. In specific embodiments, the light chain is a human light chain.

[0150] As used herein, the term “variable region” refers to a portion of an antibody, generally a portion of the light chain or heavy chain, typically the approximately 110–120 amino acids at the amino terminus or 110–125 amino acids in the mature heavy chain and approximately 90–115 amino acids in the mature light chain, which vary widely in sequence between antibodies and are used for the binding and specificity of a particular antibody to that particular antigen. Sequence variability is concentrated in a region called the complementarity-determining region (CDR), in contrast to a more highly conserved region within the variable domain, called the framework region (FR). Without wishing to be bound to a specific mechanism or theory, the CDRs of the light and heavy chains are primarily responsible for the antibody’s interaction with and specificity of the antigen. In certain embodiments, the variable region is the human variable region. In certain embodiments, the variable region includes rodent or mouse CDRs and human framework regions (FRs). In certain embodiments, the variable region is the primate (e.g., non-human primate) variable region. In certain embodiments, the variable region includes a rodent or mouse CDR and a primate (e.g., non-human primate) framework region (FR).

[0151] The terms "VL" and "VL domain" are used interchangeably to refer to the variable region of the antibody light chain.

[0152] The terms "VH" and "VH domain" are used interchangeably to refer to the heavy chain variable region of an antibody.

[0153] As used herein, the terms “constant region” and “constant domain” are interchangeable and common in the art. The constant region is the carboxyl-terminal portion of the light and / or heavy chain of an antibody moiety, for example, which is not directly involved in the binding of the antibody to the antigen but can exhibit various effector functions, such as interaction with Fc receptors (e.g., Fc gamma receptors). The constant region of an immunoglobulin (Ig) molecule generally has a much more conserved amino acid sequence compared to the immunoglobulin (Ig) variable domain.

[0154] As used herein, the term “Fc region” refers to the C-terminal region of an immunoglobulin (Ig) heavy chain, comprising at least a CH3 domain and an operably connected CH2 domain from the N to the C-terminus. In some embodiments, the Fc region includes an immunoglobulin (Ig) hinge region operably connected to the N-terminus of the CH2 domain. Examples of proteins having manipulated Fc regions can be found in Saunders 2019 (incorporated herein by reference, KO Saunders, “Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life,” 2019, Frontiers in Immunology, V. 10, Art. 1296, pp. 1–20).

[0155] As used herein, the term “EU numbering system” refers to the EU numbering regulations for constant regions of antibodies, such as those described in Edelman, GM et al., Proc. Natl. Acad. USA, 63, 78-85 (1969) and Kabat et al, Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, 5th edition, 1991, each of which is incorporated herein by reference in its entirety.

[0156] As used herein, the term “Kabat numbering system” refers to the Kabat numbering convention for the variable regions of antibodies. See, for example, Kabat et al, Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, 5th edition, 1991. Unless otherwise noted, the numbering of the variable regions of antibodies is expressed by the Kabat numbering system.

[0157] As used herein, the term “specifically binds to” refers to a molecule that binds to an antigen (e.g., an epitope or immune complex), such binding is understood by those skilled in the art. For example, a molecule that specifically binds to an antigen may also bind to other peptides or polypeptides with generally lower affinity, as determined by immunoassays, BIAcore®, KinExA 3000 instrument (Sapidyne Instruments, Boise, ID), or other assays known in the art. In specific embodiments, a molecule that specifically binds to an antigen may be a molecule that binds nonspecifically to another antigen. A K is at least 2log (e.g., coefficient 10), 2.5log, 3log, 4log, or greater than that. A The antibody binds to the antigen. Those skilled in the art will recognize that the antibodies described herein may specifically bind to more than one antigen (for example, via different regions of the antibody molecule). The term "specifically binds" includes molecules that are cross-reactive with the same antigen of different species. For example, an antigen-binding domain that specifically binds to human CD20 may be cross-reactive with CD20 of another species (e.g., cynomolgus monkey or mouse) and may still be considered to specifically bind to human CD20 as described herein.

[0158] "Affinity" refers to the total strength of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). Unless otherwise specified, "binding affinity" as used herein refers to endogenous binding affinity, which reflects the 1:1 interaction between members of a binding pair (e.g., an antigen-binding moiety and an antigen, or a receptor and its ligand). The affinity of molecule X for its partner Y can generally be expressed by the dissociation constant (KD), which is the ratio of the dissociation rate constant to the association rate constant (koff and kon, respectively). Thus, equivalent affinities may include different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by established methods known in the art, including the methods described herein. A specific method for measuring affinity is surface plasmon resonance (SPR).

[0159] The determination of the "percentage of identicalness" between two sequences (e.g., amino acid sequences or nucleic acid sequences) can be achieved using mathematical algorithms. Identity measures the percentage of identical matches between the smaller of two or more sequences, with gap alignments (if any) addressed by a specific mathematical model or computer program (i.e., the "algorithm"). A specific non-restrictive example of a mathematical algorithm used for comparing two sequences is the algorithm of Karlin S & Altschul SF (1990) PNAS 87: 2264-2268, modified as Karlin S & Altschul SF (1993) PNAS 90: 5873-5877, each of which is incorporated herein by reference in its entirety. Such algorithms are incorporated into the BLASTN, BLASTP, and BLASTX programs of Altschul SF et al., (1990) J Mol Biol 215: 403, which is also incorporated herein by reference in its entirety. BLAST nucleotide search can be performed using a set of NBLAST nucleotide program parameters, for example, with a score of 100 and a word length of 12, to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. BLAST protein search can be performed using a set of BLASTP program parameters, for example, with default settings, to obtain amino acid sequences homologous to the protein molecules described herein. Gapped BLAST can be used to obtain gapped alignments for comparison purposes, as described in Altschul SF et al., (1997) Nuc Acids Res 25: 3389-3402, which is incorporated herein by reference in its entirety. Alternatively, PSI BLAST can be used to perform iterative searches to detect intermolecular distance relationships (ibid.).When using the BLAST, Gapped BLAST, and PSI Blast programs, you can use the default parameters of each program (e.g., BLASTP and BLASTN) (see, for example, the National Center for Biotechnology Information (NCBI) World Wide Web, ncbi.nlm.nih.gov). Another specific, non-restrictive example of a mathematical algorithm used for sequence comparison is the algorithm of Myers and Miller, 1988, CABIOS 4:11–17, which is incorporated herein by reference in its entirety. Such algorithms are incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When using the ALIGN program to compare amino acid sequences, you can use the PAM120 weight residue table, gap length penalty 12, and gap penalty 4. The percentage of identical sequences between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating the percentage of identical sequences, typically only exact matches are counted. As described above, the percentage of identical proteins is based on the amino acid match between the smaller of the two proteins. Therefore, for example, using the NCBI Basic Local Alignment Tool - BLASTP program with default settings (search parameters: word size 3, expected value 0.05, hit list 100, gap cost 11,1; matrix BLOSUM62, filter string: F; genetic code: 1; window size: 40; threshold: 11; composition based statistics: 2; Karlin-Altschul statistics: lambda: 0.31293; 0.267; K: 0.132922; 0.041; H: 0.401809; 0.14; and relative statistics: effective search space: 288906), the percentage of identical proteins between sequence number 80 and sequence number 286 is 100% identical.

[0160] As used herein, the term “operably connected” refers to the linkage of functionally related polynucleotide sequence elements or amino acid sequence elements. For example, a polynucleotide sequence is operably connected when it is in a functional relationship with another polynucleotide sequence. In some embodiments, a transcriptional regulatory polynucleotide sequence, such as a promoter, enhancer, or other expression regulatory element, is operably linked to a protein-coding polynucleotide sequence if it affects the transcription of that protein-coding polynucleotide sequence.

[0161] The terms “subject” and “patient” are used interchangeably herein and include any human or non-human animal. The term “non-human animal” includes, but is not limited to, non-human primates, sheep, dogs, and vertebrates such as mice, rats, and guinea pigs. In some embodiments, the subject is human.

[0162] As used herein, the term “administer” means the physical delivery of a therapeutic agent (or a precursor of a therapeutic agent that is metabolized or altered in the subject’s body to produce the therapeutic agent in vivo) to a subject using any of the various methods and delivery systems known to those skilled in the art. Exemplary routes include, for example, intravenous, intramuscular, subcutaneous, intraperitoneal, spinal, or other parenteral routes of administration by injection or infusion. As used herein, the term “parenteral administration” means a mode of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intra-arterial, subarachnoid, lymphatic, intrafocal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, spinal, epidural, and intrasternal injections and infusions, as well as in vivo electroporation. Therapeutic agents may be administered via non-parenteral routes or orally. Other non-parenteral routes of administration include topical, cutaneous, or mucosal routes, such as intranasal, transvaginal, rectal, sublingual, or topical. Administration can also be, for example, once, multiple times, and / or over one or more extended periods.

[0163] The “therapeutic effective dose” or “therapeutic effective amount” of a drug or therapeutic agent is any amount of the drug that protects a subject from disease development or promotes disease regression, as demonstrated by a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease-free periods, or the prevention of functional impairment or disability due to the distress of the disease, when used alone or in combination with another therapeutic agent. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to those skilled in the art, for example, in human subjects during clinical trials, in animal model systems to predict efficacy in humans, or by assaying the activity of the drug in in vitro assays.

[0164] The terms “disease,” “disorder,” and “syndrome” are used interchangeably herein.

[0165] As used herein, the terms “to treat,” “to treat,” “treatment,” and others mean to alleviate or improve a disease and / or its associated symptoms, or to obtain a desired pharmacological and / or physiological effect. It is recognized that treating a disease does not preclude, but does not require, the complete disappearance of the disease or its associated symptoms. In some embodiments, the effect is therapeutic, i.e., the effect partially or completely reduces, diminishes, counteracts, mitigates, alleviates, reduces the intensity of, or cures the disease and / or any adverse symptoms that may result from the disease. In some embodiments, the effect is preventive, i.e., the effect prevents or inhibits the onset or recurrence of the disease. For this purpose, the methods disclosed herein include administering a therapeutically effective amount of the composition described herein.

[0166] 5.3 Fusion Proteins In certain embodiments, a fusion protein is provided herein that comprises an effector domain containing a catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof; and a targeting domain containing a portion that specifically binds to a target cytosolic protein.

[0167] 5.3.1 Effector Domain In some embodiments, the effector domain includes the catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof. In some embodiments, the deubiquitinating enzyme is human. In some embodiments, the catalytic domain is derived from a natural deubiquitinating enzyme (e.g., natural human deubiquitinating enzyme).

[0168] In some embodiments, the amino acid sequence of the effector domain includes the amino acid sequence of the full-length deubiquitinating enzyme. In some embodiments, the amino acid sequence of the effector domain includes the amino acid sequence of the catalytic domain of the deubiquitinating enzyme and further amino acid sequences at the N-terminus, C-terminus, or both the N-terminus and C-terminus of the catalytic domain.

[0169] In some embodiments, the catalytic domain includes the native amino acid sequence of the deubiquitinase. In some embodiments, the catalytic domain includes a variant of the native deubiquitinase. In some embodiments, the amino acid sequence of the catalytic domain of the fusion protein is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of the native deubiquitinase. In some embodiments, the amino acid sequence of the catalytic domain of the fusion protein includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 amino acid modifications compared to the amino acid sequence of the catalytic domain of the native deubiquitinase.

[0170] In some embodiments, the catalytic domain contains the smallest amino acid sequence of a native deubiquitinating enzyme sufficient to mediate the deubiquitination of the target protein. In some embodiments, the catalytic domain contains a larger amino acid sequence than the smallest of a native deubiquitinating enzyme sufficient to mediate the deubiquitination of the target protein.

[0171] In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease or a metalloprotease. In some embodiments, the deubiquitinating enzyme is a cysteine ​​protease. In some embodiments, the deubiquitinating enzyme is a metalloprotease. In some embodiments, the deubiquitinating enzyme is a ubiquitin-specific protease (USP), ubiquitin C-terminal hydrolase (UCH), Machado-Josephine domain protease (MJD), ovarian tumor protease (OTU), MINDY protease, or ZUFSP protease.

[0172] Exemplary deubiquitinating enzymes include USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, U This disclosure includes, but is not limited to, SP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, USP46, BAP1, UCHL1, UCHL3, UCHL5, ATXN3, ATXN3L, OTUB1, OTUB2, MINDY1, MINDY2, MINDY3, MINDY4, and ZUP1. Exemplary deubiquitinating enzymes for use in this disclosure are also fully disclosed in Komander, D. et al. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550-563 (2009), which is incorporated herein by reference.

[0173] In some embodiments, the deubiquitinating enzymes are USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP1 The selection is made from the group consisting of 9, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, and USP46.

[0174] In some embodiments, the deubiquitinating enzyme is BAP1, UCHL1, UCHL3, or UCHL5. In some embodiments, the deubiquitinating enzyme is ATXN3 or ATXN3L. In some embodiments, the deubiquitinating enzyme is OTUB1 or OTUB2. In some embodiments, the deubiquitinating enzyme is MINDY1, MINDY2, MINDY3, or MINDY4. In some embodiments, the deubiquitinating enzyme is ZUP1. In some embodiments, the deubiquitinating enzyme is Jab1 / Mov34 / Mpr1 Pad1 N-terminal + (MPN+) (JAMM) domain protease.

[0175] In some embodiments, the deubiquitinating enzyme is one of the deubiquitinating enzymes listed in Table 1. In some embodiments, the amino acid sequence of the deubiquitinating enzyme is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the deubiquitinating enzyme in Table 1. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequence to the catalytic domain of the deubiquitinase in Table 1. In some embodiments, the effector domain contains a functional fragment of the deubiquitinase in Table 1. In some embodiments, the effector domain of the deubiquitinase contains a functional variant of the deubiquitinase in Table 1. In some embodiments, the catalytic domain contains a functional fragment of the catalytic domain of the deubiquitinase in Table 1. In some embodiments, the catalytic domain contains a functional variant of the catalytic domain of the deubiquitinase in Table 1.

[0176] In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of sequence numbers 1 to 112.

[0177] In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 3. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 4. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 5. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 6. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 7.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 8. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 9. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 10. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 11. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 12. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 13. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 14.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 15. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 16. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 17. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 18. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 19. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 20. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 21.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 22. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 23. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 24. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 25. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 26. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 27. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 28.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 29. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 30. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 31. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 32. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 33. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 34. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 35.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 36. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 37. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 38. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 42. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 43. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 44. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 45.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 46. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 47. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 48. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 49. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 50. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 51. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 52.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 53. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 54. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 55. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 56. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 57. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 59.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 60. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 61. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 62. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 63. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 64. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 65. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 66.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 67. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 68. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 69. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 70. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 71. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 72. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 73.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 74. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 75. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 76. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 79. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 80. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 81. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 82. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 83.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 84. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 85. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 86. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 87. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 88. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 89. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 91. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 92. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 93. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 94. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 95. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 96. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 99. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 99. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 100. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 101. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 104.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 105. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 106. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 110. In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 111.In some embodiments, the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 112.

[0178] In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of any one of the catalytic domains from sequence numbers 1 to 112.

[0179] In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 1. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 2. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 3. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 4. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 6.In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 7. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 8. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 9. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 10. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 11. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 12.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 17. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 18.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 19. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 20. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 21. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 22. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 23. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 24.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 25. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 26. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 27. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 28. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 29. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 30.In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 31. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 32. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 33. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 34. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 35. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 36. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 37. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 38.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 39. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 40. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 41. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 42. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 43. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 44.In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 45. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 46. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequence to the amino acid sequence of the catalytic domain of SEQ ID NO: 47. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequence to the amino acid sequence of the catalytic domain of SEQ ID NO: 48. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 49. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 50.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequence to the amino acid sequence of the catalytic domain of SEQ ID NO: 51. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequence to the amino acid sequence of the catalytic domain of SEQ ID NO: 52. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 53. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 54. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 55. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 56.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 57. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 58. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 59. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 60. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 61. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 62.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 63. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 64. In some embodiments, the amino acid sequence of the effector domain includes an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 65. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 66. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 67. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 68. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 69. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 70. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 71.In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 72. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 73. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 74. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 75. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 76. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 77.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 78. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 79. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 80. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 81. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 82. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 83.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 84. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 85. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 86. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 87. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 88. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 89.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 90. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 91. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 92. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 93. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 94. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 95.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 96. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 97. In some embodiments, the amino acid sequence of the effector domain includes an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 98. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 99. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 100. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 101. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 102. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 103. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 104.In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 105. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 106. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 107. In some embodiments, the amino acid sequence of the effector domain contains at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 108. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 109. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 110.In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 111. In some embodiments, the amino acid sequence of the effector domain includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical amino acid sequences to the amino acid sequence of the catalytic domain of SEQ ID NO: 112.

[0180] In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme comprising an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences among sequence numbers 1 to 112.

[0181] In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 3. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 4. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 6.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 9. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 17. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 19. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 20. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 21. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 22. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 23. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 24.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 25. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 26. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 27. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 28. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 29. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 30.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 31. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 32. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 33. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 34. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 36. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 38. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 39.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 40. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 41. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 42. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 43. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 44. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 45.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 46. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 47. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 48. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 49. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 50. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 51.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 54. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 55. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 56. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 57.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 58. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 59. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 60. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 61. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 62. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 63.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 64. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 66. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 67. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 68. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 69. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 70. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 71. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 72.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 73. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 74. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 75. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 76. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 77. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 78.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 79. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 80. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 81. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 82. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 83. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 84.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 85. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 86. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 87. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 88. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 89. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 90.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 91. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 92. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 93. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 94. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 95. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 96.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 97. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 98. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 99. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 100. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 101. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 102. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 103. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 104. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 105.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 106. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 107. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 108. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 109. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 110. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 111.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112.

[0182] In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences from sequence numbers 113 to 220.

[0183] In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 113. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 115. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 116. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 117. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 119.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 120. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 121. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 122. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 123. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 124. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 125. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 126.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 127. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 128. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 129. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 130. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 131. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 132. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 133.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 134. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 135. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 136. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 137. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 138. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 139. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 140.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 141. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 142. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 143. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 144. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 145. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 146. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 147.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 148. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 149. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 150. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 151. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 152. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 153. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 154. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 155. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 156.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 157. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 158. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 159. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 160. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 161. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 162. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 163.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 164. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 165. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 166. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 167. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 168. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 169. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 170.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 171. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 172. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 173. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 174. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 175. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 176. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 177.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 178. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 179. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 180. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 181. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 182. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 183. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 184.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 185. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 186. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 187. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 188. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 189. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 190. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 191. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 192. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 193.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 194. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 195. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 196. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 197. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 198. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 199. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 200.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 201. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 202. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 203. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 204. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 205. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 206. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 207.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 208. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 209. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 210. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 211. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 213. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 214.In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 215. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 216. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 217. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 219. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 220. In some embodiments, the catalytic domain contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 286.

[0184] Table 1 below lists the amino acid sequences of exemplary human deubiquitinases and exemplary catalytic domains of exemplary human deubiquitinases. The catalytic domains are exemplary. Those skilled in the art will be able to readily determine an amino acid sequence (e.g., catalytic domain) of a human deubiquitinase sufficient to mediate deubiquitination. Any of the human deubiquitinases (its functional fragment or variant) may be used to derive a catalytic domain for use in the fusion proteins described herein.

[0185] [Table 1-1]

[0186] [Table 1-2]

[0187] [Table 1-3]

[0188] [Table 1-4]

[0189] [Table 1-5]

[0190] [Table 1-6]

[0191] [Table 1-7]

[0192] [Table 1-8]

[0193] Table 1-9

[0194] Table 1-10

[0195] Table 1-11

[0196] Table 1-12

[0197] Table 1-13

[0198] Table 1-14

[0199] Table 1-15

[0200] Table 1-16

[0201] Table 1-17

[0202] Table 1-18

[0203] Table 1-19

[0204] Table 1-20

[0205] Table 1-21

[0206] Table 1-22

[0207] Table 1-23

[0208] Table 1-24

[0209] Table 1-25

[0210] Table 1-26

[0211] Table 1-27

[0212] Table 1-28

[0213] Table 1-29

[0214] Table 1-30

[0215] Table 1-31

[0216] Table 1-32

[0217] Table 1-33

[0218] Table 1-34

[0219] Table 1-35

[0220] Table 1-36

[0221] Table 1-37

[0222] Table 1-38

[0223] Table 1-39

[0224] Table 1-40

[0225] Table 1-41

[0226] Table 1-42

[0227] Table 1-43

[0228] Table 1-44

[0229] Table 1-45

[0230] Table 1-46

[0231] Table 1-47

[0232] Table 1-48

[0233] Table 1-49

[0234] Table 1-50

[0235] Table 1-51

[0236] Table 1-52

[0237] Table 1-53

[0238] Table 1-54

[0239] Table 1-55

[0240] Table 1-56

[0241] Table 1-57

[0242] Table 1-58

[0243] Table 1-59

[0244] Table 1-60

[0245] Table 1-61

[0246] Table 1-62

[0247] Table 1-63

[0248] Table 1-64

[0249] Table 1-65

[0250] Table 1-66

[0251]

Table 1-67

[0252] Table 1-68

[0253]

Table 1-69

[0254] [Table 1-70]

[0255] [Table 1-71]

[0256] [Table 1-72]

[0257] 5.3.2 Targeting Domains In some embodiments, the targeting domain includes a targeting moiety that specifically binds to a target cytosolic protein. In some embodiments, the targeting moiety includes an antibody (or its antigen-binding fragment). In some embodiments, the antibody is a full-length antibody, a single-chain variable fragment (scFv), (scFv)2, scFv-Fc, Fab, Fab', (Fab')2, F(v), a single-domain antibody, a single-chain antibody, VHH, or (VHH)2. In some embodiments, the targeting moiety includes VHH. In some embodiments, the targeting moiety includes (VHH)2.

[0258] In some embodiments, the targeting moiety specifically binds to the wild-type target cytosolic protein. In some embodiments, the targeting moiety specifically binds to the wild-type target cytosolic protein but does not specifically bind to variants of the target cytosolic protein associated with hereditary diseases. In some embodiments, the targeting moiety specifically binds to native variants of the target cytosolic protein. In some embodiments, the targeting moiety specifically binds to native variants of the target cytosolic protein associated with hereditary diseases (e.g., hereditary diseases described herein). In some embodiments, the targeting moiety specifically binds to native variants of the target cytosolic protein that are the cause of hereditary diseases (e.g., hereditary diseases described herein). In some embodiments, the targeting moiety specifically binds to native variants of the target cytosolic protein that are loss-of-function variants. In some embodiments, the targeting moiety specifically binds to native variants of the target cytosolic protein that are loss-of-function variants associated with hereditary diseases (e.g., hereditary diseases described herein). In some embodiments, the targeting portion specifically binds to a native variant of the target cytosolic protein, which is a loss-of-function variant that causes a genetic disorder (e.g., a genetic disorder as described herein).

[0259] 5.3.2.1 Exemplary target cytosolic proteins In some embodiments, the targeting moiety specifically binds to a target cytosolic protein (e.g., cytosolic proteins described herein). Exemplary target cytosolic proteins include Ras / Rap GTPase activating protein (SYNGAP1), cyclin-dependent kinase-like protein 5 (CDKL5), copper transport ATPase 2 (ATP7B), syntaxin-binding protein 1 (STXBP1), progranulin (GRN), jagged protein 1 (JAG1), GATOR complex protein DEPDC5 (DEPDC5), tuberine (TSC2), hamartin (TSC1), kinesin-like protein KIF1A (KIF1A), dynamin-1 (DNM1), SH3, and multiplex. This includes, but is not limited to, cytoplasmic dynein repeat domain protein 3 (SHANK3), dystrophin (DMD), oxygen regulatory protein 1 (RP1), titin (TTN), cytoplasmic dynein 1 heavy chain 1 (DYNC1H1), TRIO and F-actin binding proteins (TRIO), high-potential ubiquitin carboxyl-terminal hydrolase FAF-X (USP9X), cystatin B (CSTB), and pterin-4-alpha-carbinolamine dehydratase (PCBD1).

[0260] In some embodiments, the target cytosolic protein is SYNGAP1. In some embodiments, the target cytosolic protein is CDKL5. In some embodiments, the target cytosolic protein is ATP7B. In some embodiments, the target cytosolic protein is STXBP1. In some embodiments, the target cytosolic protein is GRN. In some embodiments, the target cytosolic protein is JAG1. In some embodiments, the target cytosolic protein is DEPDC5. In some embodiments, the target cytosolic protein is TSC2. In some embodiments, the target cytosolic protein is TSC1. In some embodiments, the target cytosolic protein is KIF1A. In some embodiments, the target cytosolic protein is DNM1. In some embodiments, the target cytosolic protein is SHANK3. In some embodiments, the target cytosolic protein is DMD. In some embodiments, the target cytosolic protein is TNT. In some embodiments, the target cytosolic protein is DYNC1H1. In some embodiments, the target cytosolic protein is TRIO. In some embodiments, the target cytosolic protein is USP9X. In some embodiments, the target cytosolic protein is TRIO. In some embodiments, the target cytosolic protein is USP9X. In some embodiments, the target cytosolic protein is CSTB. In some embodiments, the target cytosolic protein is USP9X. In some embodiments, the target cytosolic protein is PCBD1.

[0261] In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 221. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 222. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 223. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 224. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 225. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 226. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 227. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 228. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 229.In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 230. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 231. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 232. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 233. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 234. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 235. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 236. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 237. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 238.In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 287. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 288. In some embodiments, the target cytosolic protein contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 289.

[0262] Table 2 below provides the wild-type amino acid sequences of exemplary proteins for targeting for deubiquitination using the fusion proteins described herein.

[0263] [Table 2-1]

[0264] [Table 2-2]

[0265] [Table 2-3]

[0266] [Table 2-4]

[0267] [Table 2-5]

[0268] [Table 2-6]

[0269] Table 2-7

[0270] Table 2-8

[0271] Table 2-9

[0272] Table 2-10

[0273] Table 2-11

[0274] Table 2-12

[0275] Table 2-13

[0276] Table 2-14

[0277] Table 2-15

[0278] Table 2-16

[0279] Table 2-17

[0280] Table 2-18

[0281] Table 2-19

[0282] Table 2-20

[0283] Table 2-21

[0284] Table 2-22

[0285] Table 2-23

[0286] Table 2-24

[0287] Table 2-25

[0288] Table 2-26

[0289] Table 2-27

[0290] Table 2-28

[0291] Table 2-29

[0292] Table 2-30

[0293] Table 2-31

[0294] Table 2-32

[0295] Table 2-33

[0296] Table 2-34

[0297] Table 2-35

[0298] 5.3.2.2 Anti-SYNGAP1 single-domain antibody In one embodiment, a single-domain antibody (e.g., VHH) that specifically binds to SYNGAP1 (e.g., human SYNGAP1) is provided herein. In some embodiments, the single-domain antibody is a VHH (i.e., a nanobody). In some embodiments, the VHH comprises three complementarity-determining regions: VH CDR1, VH CDR2, and VH CDR3. The following CDRs are defined by Kabat.

[0299] In some embodiments, VHH is CDR1 containing the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, or the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); or the amino acid sequence of SEQ ID NOs. 291, 295, 299, 303, 307, or 311, or one, two, or three amino acid modifications ( CDR2 includes the amino acid sequence of SEQ ID NO: 291, 295, 299, 303, 307, or 311, which has, for example, substitutions, deletions, or additions; and / or CDR3 includes the amino acid sequence of SEQ ID NO: 292, 296, 300, 304, 308, or 312, or the amino acid sequence of SEQ ID NO: 292, 296, 300, 304, 308, or 312, which has one, two, or three amino acid modifications (e.g., substitutions, deletions, or additions).

[0300] In some embodiments, VHH includes CDR1 containing the amino acid sequence of SEQ ID NO: 290, or the amino acid sequence of SEQ ID NO: 290 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 291, or the amino acid sequence of SEQ ID NO: 291 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 292, or the amino acid sequence of SEQ ID NO: 292 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0301] In some embodiments, VHH includes CDR1 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 290; CDR2 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 291; and CDR3 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 292.

[0302] In some embodiments, VHH includes CDR1 containing the amino acid sequence of SEQ ID NO: 294, or the amino acid sequence of SEQ ID NO: 294 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 295, or the amino acid sequence of SEQ ID NO: 295 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 296, or the amino acid sequence of SEQ ID NO: 296 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0303] In some embodiments, VHH includes CDR1 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 294; CDR2 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 295; and CDR3 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 296.

[0304] In some embodiments, VHH includes VH CDR1 containing the amino acid sequence of SEQ ID NO: 298, or the amino acid sequence of SEQ ID NO: 298 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 299, or the amino acid sequence of SEQ ID NO: 299 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 300, or the amino acid sequence of SEQ ID NO: 300 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0305] In some embodiments, VHH includes CDR1 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 298; CDR2 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 299; and CDR3 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 300.

[0306] In some embodiments, VHH includes CDR1 containing the amino acid sequence of SEQ ID NO: 302, or the amino acid sequence of SEQ ID NO: 302 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 303, or the amino acid sequence of SEQ ID NO: 303 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 304, or the amino acid sequence of SEQ ID NO: 304 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0307] In some embodiments, VHH includes CDR1 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 302; CDR2 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 303; and CDR3 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 304.

[0308] In some embodiments, VHH includes CDR1 containing the amino acid sequence of SEQ ID NO: 306, or the amino acid sequence of SEQ ID NO: 306 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 307, or the amino acid sequence of SEQ ID NO: 307 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 308, or the amino acid sequence of SEQ ID NO: 308 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0309] In some embodiments, VHH includes CDR1 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 306; CDR2 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 307; and CDR3 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 308.

[0310] In some embodiments, VHH includes CDR1 containing the amino acid sequence of SEQ ID NO: 310, or the amino acid sequence of SEQ ID NO: 310 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 311, or the amino acid sequence of SEQ ID NO: 311 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 312, or the amino acid sequence of SEQ ID NO: 312 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0311] In some embodiments, VHH includes CDR1 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 310; CDR2 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 311; and CDR3 containing an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312.

[0312] In some embodiments, VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NOs. 293, 297, 301, 305, 309, or 312.

[0313] In some embodiments, VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 293.

[0314] In some embodiments, VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 297.

[0315] In some embodiments, VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 301.

[0316] In some embodiments, VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 305.

[0317] In some embodiments, VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 309.

[0318] In some embodiments, VHH contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 313.

[0319] (VHH)2 antibodies that specifically bind to SYNGAP1 are also provided herein. The first and second VHHs of (VHH)2 may be directly linked or indirectly linked via an amino acid linker. An exemplary amino acid linker includes one of the amino acid sequences from SEQ ID NOs. 375 to 384. In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to one of the amino acid sequences from SEQ ID NOs. 375 to 384. In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO. 375. In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO. 376. In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 377. In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 378. In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 379. In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 380. In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 381. In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 382. In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 383.In some embodiments, the amino acid sequence of the linker is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 384.

[0320] In some embodiments, (VHH)2 is CDR1 containing the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, or the amino acid sequence of SEQ ID NOs. 291, 295, 299, 303, 307, or 31 CDR2 containing the amino acid sequence of SEQ ID NO: 291, 295, 299, 303, 307, or 311 with modifications (e.g., substitution, deletion, or addition); and / or CDR3 containing the amino acid sequence of SEQ ID NO: 292, 296, 300, 304, 308, or 312 or the amino acid sequence of SEQ ID NO: 292, 296, 300, 304, 308, or 312 with one, two, or three amino acid modifications (e.g., substitution, deletion, or addition). First VHH; CDR1 containing the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, or having 1, 2, or 3 amino acid modifications (e.g., substitution, deletion, or addition); amino acid sequence of SEQ ID NOs. 291, 295, 299, 303, 307, or 311, or having 1, 2, or 3 amino acid modifications (e.g., substitution, deletion) A second VHH comprising CDR2 containing the amino acid sequence of SEQ ID NO: 291, 295, 299, 303, 307, or 311 having (substitution, deletion, or addition); and / or a second VHH comprising CDR3 containing the amino acid sequence of SEQ ID NO: 292, 296, 300, 304, 308, or 312 or the amino acid sequence of SEQ ID NO: 292, 296, 300, 304, 308, or 312 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0321] In some embodiments, (VHH)2 includes a first VHH comprising: CDR1 containing the amino acid sequence of SEQ ID NO: 290 or the amino acid sequence of SEQ ID NO: 290 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 291 or the amino acid sequence of SEQ ID NO: 291 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 292 or the amino acid sequence of SEQ ID NO: 292 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition), wherein the first VHH comprises a second VH A second VHH is operably connected to H (may be via an amino acid linker), and the second VHH includes CDR1 containing the amino acid sequence of SEQ ID NO: 290, or the amino acid sequence of SEQ ID NO: 290 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 291, or the amino acid sequence of SEQ ID NO: 291 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 292, or the amino acid sequence of SEQ ID NO: 292 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0322] In some embodiments, (VHH)2 includes a first VHH comprising: CDR1 containing the amino acid sequence of SEQ ID NO: 294 or the amino acid sequence of SEQ ID NO: 294 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 295 or the amino acid sequence of SEQ ID NO: 295 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 296 or the amino acid sequence of SEQ ID NO: 296 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition), wherein the first VHH comprises a second VH A second VHH is operably connected to H (may be via an amino acid linker), and the second VHH includes CDR1 containing the amino acid sequence of SEQ ID NO: 294, or the amino acid sequence of SEQ ID NO: 294 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 295, or the amino acid sequence of SEQ ID NO: 295 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 296, or the amino acid sequence of SEQ ID NO: 296 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0323] In some embodiments, (VHH)2 includes a first VHH comprising: CDR1 containing the amino acid sequence of SEQ ID NO: 298 or the amino acid sequence of SEQ ID NO: 298 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 299 or the amino acid sequence of SEQ ID NO: 299 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 300 or the amino acid sequence of SEQ ID NO: 300 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition), wherein the first VHH comprises a second VH A second VHH is operably connected to H (may be via an amino acid linker), and includes CDR1 containing the amino acid sequence of SEQ ID NO: 298, or the amino acid sequence of SEQ ID NO: 298 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 299, or the amino acid sequence of SEQ ID NO: 299 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 300, or the amino acid sequence of SEQ ID NO: 300 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0324] In some embodiments, (VHH)2 includes a first VHH comprising: CDR1 containing the amino acid sequence of SEQ ID NO: 302 or the amino acid sequence of SEQ ID NO: 302 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 303 or the amino acid sequence of SEQ ID NO: 303 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 304 or the amino acid sequence of SEQ ID NO: 304 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition), wherein the first VHH is operably connected to a second VHH (may be via an amino acid linker), and the second VHH comprises a VHH containing the amino acid sequence of SEQ ID NO: 302 or the amino acid sequence of SEQ ID NO: 302 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition). CDR1; CDR2 containing the amino acid sequence of SEQ ID NO: 303, or the amino acid sequence of SEQ ID NO: 303 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 304, or the amino acid sequence of SEQ ID NO: 304 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0325] In some embodiments, (VHH)2 includes a first VHH comprising: CDR1 containing the amino acid sequence of SEQ ID NO: 306 or the amino acid sequence of SEQ ID NO: 306 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 307 or the amino acid sequence of SEQ ID NO: 307 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 308 or the amino acid sequence of SEQ ID NO: 308 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition), wherein the first VHH comprises a second VH A second VHH is operably connected to H (may be via an amino acid linker), and the second VHH includes CDR1 containing the amino acid sequence of SEQ ID NO: 306, or the amino acid sequence of SEQ ID NO: 306 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 307, or the amino acid sequence of SEQ ID NO: 307 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 308, or the amino acid sequence of SEQ ID NO: 308 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0326] In some embodiments, (VHH)2 includes a first VHH comprising: CDR1 containing the amino acid sequence of SEQ ID NO: 310 or the amino acid sequence of SEQ ID NO: 310 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 311 or the amino acid sequence of SEQ ID NO: 311 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 312 or the amino acid sequence of SEQ ID NO: 312 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition), wherein the first VHH comprises a second VH A second VHH is operably connected to H (may be via an amino acid linker), and the second VHH includes CDR1 containing the amino acid sequence of SEQ ID NO: 310, or the amino acid sequence of SEQ ID NO: 310 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); CDR2 containing the amino acid sequence of SEQ ID NO: 311, or the amino acid sequence of SEQ ID NO: 311 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); and CDR3 containing the amino acid sequence of SEQ ID NO: 312, or the amino acid sequence of SEQ ID NO: 312 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0327] In some embodiments, (VHH)2 includes a first VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NOs. 293, 297, 301, 305, 309, or 313; and a second VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NOs. 293, 297, 301, 305, 309, or 313.

[0328] In some embodiments, (VHH)2 includes a first VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 293; and a second VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 293.

[0329] In some embodiments, (VHH)2 includes a first VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 297; and a second VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 297.

[0330] In some embodiments, (VHH)2 includes a first VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 301; and a second VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 301.

[0331] In some embodiments, (VHH)2 includes a first VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 305; and a second VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 305.

[0332] In some embodiments, (VHH)2 includes a first VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 309; and a second VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 309.

[0333] In some embodiments, (VHH)2 includes a first VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 313; and a second VHH having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 313.

[0334] In some embodiments, (VHH)2 contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 314. In some embodiments, (VHH)2 contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 315. In some embodiments, (VHH)2 contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 316. In some embodiments, (VHH)2 contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 317. In some embodiments, (VHH)2 contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318. In some embodiments, (VHH)2 contains an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 319.

[0335] In some embodiments, the anti-SYNGAP1 VHH is as described in Table 3.

[0336] The amino acid sequence of anti-SYNGAP1 VHH is provided in Table 3 below.

[0337] [Table 3]

[0338] The amino acid sequence of anti-SYNGAP1 VHH2 is provided in Table 4 below.

[0339] [Table 4]

[0340] 5.3.3 Orientation and Linker In some embodiments, the effector domain is the N-terminus of the targeting domain in the fusion protein. In some embodiments, the targeting domain is the N-terminus of the effector domain in the fusion protein. In some embodiments, the effector domain is operably connected (directly or indirectly) to the C-terminus of the targeting domain. In some embodiments, the effector domain is operably connected (directly or indirectly) to the N-terminus of the targeting domain. In some embodiments, the effector domain is directly operably connected to the C-terminus of the targeting domain. In some embodiments, the effector domain is directly operably connected to the N-terminus of the targeting domain.

[0341] In some embodiments, the effector domain is operably connected indirectly to the C-terminus of the targeting domain. In some embodiments, the effector domain is operably connected indirectly to the N-terminus of the targeting domain. One or more amino acid sequences, including, for example, a linker or encoding one or more polypeptides, may be located between the effector and targeting portions. In some embodiments, the effector domain is operably connected indirectly to the C-terminus of the targeting domain via a peptide linker. In some embodiments, the effector domain is operably connected indirectly to the N-terminus of the targeting domain via a peptide linker.

[0342] Each component of the fusion protein described herein may be directly linked to the other, or indirectly linked to the other via a peptide linker. In some embodiments, the linker is one or any combination of a cleavable linker, an incleavable linker, a peptide linker, a mobile linker, a rigid linker, a helical linker, or a non-helical linker. In some embodiments, the linker is a peptide linker. In some embodiments, the linker is a peptide linker containing glycine or serine, or both glycine and serine amino acid residues. In some embodiments, the peptide linker contains 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids, or about 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids. In some embodiments, the linker is a peptide linker consisting of glycine or serine, or both glycine and serine amino acid residues. In some embodiments, the peptide linker consists of 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids, or approximately 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids. In some embodiments, the peptide linker contains at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid residues. In some embodiments, the linker is at least 11 amino acid long. In some embodiments, the linker is at least 15 amino acid long.In some embodiments, the linker has a length of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid residues.

[0343] In some embodiments, the linker is a glycine / serine linker, for example, a peptide linker substantially composed of the amino acids glycine and serine. In some embodiments, the linker is a glycine / serine / proline linker, for example, a peptide linker substantially composed of the amino acids glycine, serine, and proline.

[0344] In some embodiments, the linker amino acid sequence comprises one amino acid sequence from sequence numbers 375-384 or 402-519, or one amino acid sequence from sequence numbers 375-384 or 402-519 including one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0345] In some embodiments, the linker amino acid sequence comprises one amino acid sequence from sequence numbers 375 to 384, or one amino acid sequence from sequence numbers 375 to 384 that includes one, two, or three amino acid modifications (e.g., substitution, deletion, or addition).

[0346] Exemplary linker amino acid sequences for use in any one or more of the fusion proteins described herein are provided in Table 5 below.

[0347] [Table 5-1]

[0348] [Table 5-2]

[0349] [Table 5-3]

[0350] 5.3.3.1 Conditional structures Constructs comprising a targeting domain (e.g., VHH, (VHH)2) bound to an effector domain (e.g., an effector domain containing a catalytic domain of a deubiquitinating enzyme, or an effector domain containing a deubiquitinating enzyme) are also described herein. In some embodiments, the linkage between the targeting domain and the effector domain is mediated by the binding of a first active substance (e.g., a small molecule, protein, or peptide) bound to the targeting domain to a second active substance (e.g., a small molecule, protein, or peptide) bound to the effector domain. For example, in one embodiment, the targeting domain may be bound to a first active substance that specifically binds to the second active substance bound to the effector domain. In some embodiments, the specific binding of the first active substance to the second active substance is mediated by the addition of a third active substance (e.g., a small molecule).

[0351] For example, a conditional construct including a KBP / FRB-based dimerization switch, as described herein by example in U.S. Patent Application Publication No. 2017 / 0081411 (the entire content of which is incorporated herein by reference), may be utilized herein. FKBP12 (FKBP or FK506-binding protein) is an abundant cytoplasmic protein that serves as the primary intracellular target for the natural product immunosuppressant, rapamycin. Rapamycin binds to FKBP and its large PI3K homolog FRAP (RAFT, mTOR), thereby acting to dimerize these molecules. In some embodiments, the FKBP / FRAP-based switch, also referred herein as an FKBP / FRB-based switch, may utilize a heterodimerizing molecule, such as rapamycin or a rapamycin analog. FRB is a 93-amino acid portion of FRAP sufficient to bind to the FKBP-rapamycin complex (its full content is incorporated herein by reference: Chen, J., Zheng, XF, Brown, EJ & Schreiber, SL (1995) Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 92: 4947-51). For example, the targeting domain can be bound to FKBP, and the effector domain can be bound to FRB. Therefore, the linkage between the targeting domain and the effector domain is mediated by rapamycin and occurs only in the presence of rapamycin.

[0352] Illustrative conditional activation systems that can be used herein include U.S. Patent Application Publication No. 2017 / 0081411, the entire contents of which are incorporated herein by reference for all purposes; Lajoie MJ, et al. Designed protein logic to target cells with precise combinations of surface antigens. Science. 2020 Sep 25;369(6511):1637-1643. doi: 10.1126 / science.aba6527. Epub 2020 Aug 20. PMID: 32820060; Farrants H, et al. Chemogenetic Control of Nanobodies. Nat Methods. 2020 Mar;17(3):279-282. doi: 10.1038 / s41592-020-0746-7. Epub 2020 Feb 17. PMID: This includes, but is not limited to, those described in 32066961 and U.S. Patent Application Publication No. 2017 / 0081411.

[0353] 5.3.4 Exemplary Fusion Proteins Exemplary fusion proteins are listed below. Exemplary fusion proteins of this disclosure include, but are not limited to, the following: In some embodiments, the fusion protein comprises an effector domain containing a catalytic domain of a cysteine ​​protease deubiquitinating enzyme, or a functional fragment or functional variant thereof; and a targeting domain containing a targeting moiety that specifically binds to a cytosolic protein, the cytosolic protein being CDKL5, ATP7B, STXBP1, SYNGAP1, GRN, JAG1, DEPDC5, TSC2, TSC1, KIF1A, DNM1, SHANK3, DMD, RP1, TTN, DYNC1H1, TRIO, USP9X, PYDC2, CSTB, or PCBD1.

[0354] In some embodiments, the fusion protein comprises an effector domain containing a catalytic domain of a metalloproteinase deubiquitinating enzyme, or a functional fragment or functional variant thereof; and a targeting domain containing a targeting moiety that specifically binds to a cytosolic protein, the cytosolic protein being CDKL5, ATP7B, STXBP1, SYNGAP1, GRN, JAG1, DEPDC5, TSC2, TSC1, KIF1A, DNM1, SHANK3, DMD, RP1, TTN, DYNC1H1, TRIO, or USP9X, PYDC2, CSTB, or PCBD1.

[0355] In some embodiments, the fusion protein comprises an effector domain containing a catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof, wherein the deubiquitinating enzyme is a ubiquitin-specific protease (USP), ubiquitin C-terminal hydrolase (UCH), Machado-Josephine domain protease (MJD), ovarian tumor protease (OTU), MINDY protease, or ZUFSP protease; and a targeting domain containing a targeting portion that specifically binds to a cytosolic protein, wherein the cytosolic protein is CDKL5, ATP7B, STXBP1, SYNGAP1, GRN, JAG1, DEPDC5, TSC2, TSC1, KIF1A, DNM1, SHANK3, DMD, RP1, TTN, DYNC1H1, TRIO, USP9X, PYDC2, CSTB, or PCBD1.

[0356] In one embodiment, the fusion protein is an effector domain comprising the catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof, wherein the deubiquitinating enzyme is USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP 16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, U SP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37 The targeting domain comprises an effector domain which is USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, USP46, BAP1, UCHL1, UCHL3, UCHL5, ATXN3, ATXN3L, OTUB1, OTUB2, MINDY1, MINDY2, MINDY3, MINDY4, or ZUP1; and a targeting domain which comprises a targeting moiety that specifically binds to a cytosolic protein, wherein the cytosolic protein is CDKL5, ATP7B, STXBP1, SYNGAP1, GRN, JAG1, DEPDC5, TSC2, TSC1, KIF1A, DNM1, SHANK3, DMD, RP1, TTN, DYNC1H1, TRIO, USP9X, PYDC2, CSTB, or PCBD1.

[0357] In one embodiment, the fusion protein comprises an effector domain containing a catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof, wherein the deubiquitinating enzyme is one of the effector domains listed in Table 1; and a targeting domain containing a targeting portion that specifically binds to a cytosolic protein, wherein the cytosolic protein is CDKL5, ATP7B, STXBP1, SYNGAP1, GRN, JAG1, DEPDC5, TSC2, TSC1, KIF1A, DNM1, SHANK3, DMD, RP1, TTN, DYNC1H1, TRIO, USP9X, PYDC2, CSTB, or PCBD1.

[0358] In one embodiment, the fusion protein comprises an effector domain containing a catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof, wherein the catalytic domain is listed in Table 1; and a targeting domain containing a targeting moiety that specifically binds to a cytosolic protein, wherein the cytosolic protein is CDKL5, ATP7B, STXBP1, SYNGAP1, GRN, JAG1, DEPDC5, TSC2, TSC1, KIF1A, DNM1, SHANK3, DMD, RP1, TTN, DYNC1H1, TRIO, USP9X, PYDC2, CSTB, or PCBD1.

[0359] In one embodiment, the fusion protein is an effector domain containing the catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof, wherein the deubiquitinating enzyme contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs: 1 to 112. The targeting domain comprises an effector domain and a targeting moiety that specifically binds to a cytosolic protein, wherein the cytosolic protein is CDKL5, ATP7B, STXBP1, SYNGAP1, GRN, JAG1, DEPDC5, TSC2, TSC1, KIF1A, DNM1, SHANK3, DMD, RP1, TTN, DYNC1H1, TRIO, USP9X, PYDC2, CSTB, or PCBD1.

[0360] In one embodiment, the fusion protein is an effector domain comprising a catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof, wherein the catalytic domain has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of sequence numbers 113-220 or 286. The targeting domain comprises an effector domain including a column; and a targeting domain including a targeting portion that specifically binds to a cytosolic protein, wherein the cytosolic protein is CDKL5, ATP7B, STXBP1, SYNGAP1, GRN, JAG1, DEPDC5, TSC2, TSC1, KIF1A, DNM1, SHANK3, DMD, RP1, TTN, DYNC1H1, TRIO, USP9X, PYDC2, CSTB, or PCBD1.

[0361] In one embodiment, the fusion protein is an effector domain comprising the catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof, wherein the deubiquitinating enzyme comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence of any one of SEQ ID NOs: 1 to 112. A targeting domain comprising an effector domain containing identical amino acid sequences and a targeting portion that specifically binds to a cytosolic protein, wherein the cytosolic protein comprises a targeting domain containing an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to one of the amino acid sequences from sequence numbers 221-238 or 287-289.

[0362] In one embodiment, the fusion protein is an effector domain comprising a catalytic domain of a deubiquitinating enzyme, or a functional fragment or functional variant thereof, wherein the catalytic domain comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 1 A targeting domain comprising an effector domain containing 00% identical amino acid sequences and a targeting moiety that specifically binds to a cytosolic protein, wherein the cytosolic protein comprises the targeting domain containing an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences from sequence numbers 221-238 or 287-289.

[0363] The amino acid sequences of exemplary SYNGAP1 targeting fusion proteins are provided in Table 6 below.

[0364] [Table 6-1]

[0365] Table 6-2

[0366] Table 6-3

[0367] Table 6-4

[0368] Table 6-5

[0369] Table 6-6

[0370] Table 6-7

[0371] Table 6-8

[0372] Table 6-9

[0373] Table 6-10

[0374] Table 6-11

[0375] Table 6-12

[0376] Table 6-13

[0377] Table 6-14

[0378] In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences from SEQ ID NO: 320 to 367. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 320. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 321. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 322. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 323. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 324. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 325.In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 326. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 327. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 328. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 329. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 330. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 331. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 332.In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 333. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 334. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 335. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 336. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 337. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 338. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 339.In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 340. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 341. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 342. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 343. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 344. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 346.In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 347. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 348. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 349. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 350. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 351. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 352. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 353.In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 354. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 355. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 356. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 357. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 358. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 359. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 360. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 361.In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 362. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 363. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 364. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 365. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 366. In some embodiments, the fusion protein contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 367.

[0379] In some embodiments, the fusion protein consists of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences from SEQ ID NO: 320 to 367. In some embodiments, the fusion protein consists of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 320. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 321. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 322. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 323. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 324. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 325.In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 326. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 327. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 328. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 329. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 330. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 331. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 332.In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 333. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 334. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 335. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 336. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 337. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 338. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 339.In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 340. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 341. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 342. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 343. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 344. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 346.In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 347. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 348. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 349. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 350. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 351. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 352. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 353.In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 354. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 355. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 356. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 357. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 358. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 359. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 360. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 361.In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 362. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 363. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 364. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 365. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 366. In some embodiments, the fusion protein has an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 367.

[0380] 5.3.4.1 Further Exemplary Embodiments Further exemplary embodiments of the fusion proteins described herein, which should not be construed as limiting, are provided below.

[0381] Embodiment 1. (a) A fusion protein comprising an effector moiety comprising a functional fragment of a human deubiquitinating enzyme capable of mediating deubiquitination, wherein the human deubiquitinating enzyme comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs: 1 to 112, and a targeting moiety comprising VHH, (VHH)2, or scFv that specifically binds to a cytosolic protein.

[0382] Embodiment 2. A fusion protein comprising an effector moiety containing a functional fragment of a human deubiquitinase capable of mediating deubiquitination, which contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences among SEQ ID NOs: 113-220 or 286; and a targeting moiety containing VHH, (VHH)2, or scFv that specifically binds to a cytosolic protein.

[0383] Embodiment 3. A fusion protein comprising an effector moiety containing a functional fragment of a human deubiquitinase capable of mediating deubiquitination, having an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 286, and a targeting moiety containing VHH, (VHH)2, or scFv that specifically binds to a cytosolic protein.

[0384] Embodiment 4. The cytosolic proteins include cyclin-dependent kinase-like protein 5 (CDKL5), copper transport ATPase 2 (ATP7B), syntaxin-binding protein 1 (STXBP1), and Ras / Rap A fusion protein from any one of Embodiments 1 to 3, which is GTPase-activated protein (SYNGAP1), progranulin (GRN), jagged 1 protein (JAG1), GATOR complex protein DEPDC5 (DEPDC5), tuberine (TSC2), hamartin (TSC1), kinesin-like protein KIF1A (KIF1A), dynamin-1 (DNM1), SH3 and multiple ankyrin repeat domain protein 3 (SHANK3), dystrophin (DMD), oxygen regulatory protein 1 (RP1), titin (TTN), cytoplasmic dynein 1 heavy chain 1 (DYNC1H1), TRIO and F-actin-binding protein (TRIO), high-potential ubiquitin carboxyl-terminal hydrolase FAF-X (USP9X), pyrin domain-containing protein 2 (PYDC2), cystatin B (CSTB), or pterin-4-alpha-carbinolamine dehydratase (PCBD1).

[0385] Embodiment 5. A fusion protein of any one of Embodiments 1 to 4, wherein the cytosolic protein is SHANK3, SYNGAP1, PYCD2, CSTB, or PCBD1.

[0386] Embodiment 6. A fusion protein of any one of Embodiments 1 to 5, wherein the cytosolic protein is SHANK3, SYNGAP1, CSTB, or PCBD1.

[0387] Embodiment 7. A fusion protein of any one of Embodiments 1 to 6, wherein the cytosolic protein is SYNGAP1.

[0388] Embodiment 8. A fusion protein of any one of Embodiments 1 to 7, wherein the targeting portion is VHH or (VHH)2.

[0389] Embodiment 9. A fusion protein of any one of Embodiments 1 to 8, wherein the targeting portion includes the VHH listed in Table 3.

[0390] Embodiment 10. A fusion protein from any one of Embodiments 1 to 9, wherein the targeting portion comprises a VHH including CDR1, CDR2, and CDR3 of the VHHs listed in Table 3.

[0391] Embodiment 11. The VHH is a CDR1 containing the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, or having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition); the amino acid sequence of SEQ ID NOs. 291, 295, 299, 303, 307, or 311, or having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition). A fusion protein comprising any one of Embodiments 1 to 10, comprising: CDR2 comprising the amino acid sequence of SEQ ID NO: 291, 295, 299, 303, 307, or 311 having ); and / or CDR3 comprising the amino acid sequence of SEQ ID NO: 292, 296, 300, 304, 308, or 312 having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition) of SEQ ID NO: 292, 296, 300, 304, 308, or 312.

[0392] Embodiment 12. A fusion protein of any one of Embodiments 1 to 11, wherein the targeting portion comprises a VHH having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the VHH described in Table 3.

[0393] Embodiment 13. A fusion protein of any one of Embodiments 1 to 12, wherein the targeting portion comprises a VHH having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs. 293, 297, 301, 305, 309, or 313.

[0394] Embodiment 14. A fusion protein of any one of Embodiments 1 to 13, wherein the targeting portion comprises (VHH)2, which includes a first VHH and a second VHH as described in Table 3.

[0395] Embodiment 15. The fusion protein of Embodiment 14, wherein the amino acid sequence of the first VHH is 100% identical to the amino acid sequence of the second VHH.

[0396] Embodiment 16. A fusion protein from any one of Embodiments 14 to 15, wherein the first (VHH)2 comprises CDR1, CDR2, and CDR3 of VHH as described in Table 3; and the second (VHH)2 comprises CDR1, CDR2, and CDR3 of VHH as described in Table 3.

[0397] Embodiment 17. The first (VHH)2 is a CDR1 comprising the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, or the amino acid sequence of SEQ ID NOs. 291, 295, 299, 303, 307, or 31 CDR2 comprising the amino acid sequence of SEQ ID NO: 291, 295, 299, 303, 307, or 311 having deletions or additions; and / or CDR3 comprising the amino acid sequence of SEQ ID NO: 292, 296, 300, 304, 308, or 312 or the amino acid sequence of SEQ ID NO: 292, 296, 300, 304, 308, or 312 having one, two, or three amino acid modifications (e.g., substitutions, deletions, or additions); the first (VHH)2 is , CDR1 containing the amino acid sequence of SEQ ID NOs. 290, 294, 298, 302, 306, or 310, or having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition);1, 295, 299, 303, 307, or 311, or having one, two, or three amino acid modifications (e.g., substitution, deletion, or addition) A fusion protein comprising any one of Embodiments 14 to 16, comprising: CDR2 containing the amino acid sequence of SEQ ID NO: 291, 295, 299, 303, 307, or 311; and / or CDR3 containing the amino acid sequence of SEQ ID NO: 292, 296, 300, 304, 308, or 312 having one, two, or three amino acid modifications (e.g., substitution, deletion, ...

Claims

1. a. an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or variant thereof, b. A targeting domain that includes a targeting moiety that specifically binds to a cytosolic protein. An effector domain operably linked to: A nucleic acid molecule encoding a fusion protein comprising:

2. 2. The nucleic acid molecule of claim 1, wherein the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 80, 1-79, or 81-112.

3. 2. The nucleic acid molecule of claim 1, wherein the catalytic domain comprises a catalytic domain derived from a deubiquitinase that comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 80, 1-79, or 81-112.

4. 2. The nucleic acid molecule of claim 1, wherein the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 286, or 113-220.

5. The nucleic acid molecule of claim 1 , wherein the portion that specifically binds to a cytosolic protein comprises an antibody, or a functional fragment or functional variant thereof.

6. The nucleic acid molecule of claim 5 , wherein the antibody, or functional fragment or functional variant thereof, comprises a VHH.

7. The cytosolic proteins include SH3 and multiple ankyrin repeat domain protein 3 (SHANK3), cyclin-dependent kinase-like 5 (CDKL5), copper-transporting ATPase 2 (ATP7B), syntaxin-binding protein 1 (STXBP1), Ras / Rap 2. The nucleic acid molecule of claim 1, which is GTPase activating protein (SYNGAP1), progranulin (GRN), Jagged 1 protein (JAG1), GATOR complex protein DEPDC5 (DEPDC5), tuberin (TSC2), hamartin (TSC1), kinesin-like protein KIF1A (KIF1A), dynamin-1 (DNM1), dystrophin (DMD), oxygen-regulated protein 1 (RP1), titin (TTN), cytoplasmic dynein 1 heavy chain 1 (DYNC1H1), TRIO and F-actin binding protein (TRIO), highly probable ubiquitin carboxyl-terminal hydrolase FAF-X (USP9X), cystatin B (CSTB), or pterin-4-alpha-carbinolamine dehydratase (PCBD1).

8. 2. The nucleic acid molecule of claim 1, wherein the cytosolic protein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 232, 221-231, 233-328 or 287-289.

9. The nucleic acid molecule of claim 1 , wherein the effector domain is indirectly operably linked to the targeting domain via a peptide linker.

10. The nucleic acid molecule of claim 1 which is a DNA molecule or an RNA molecule.

11. A vector comprising the nucleic acid molecule described in claim 1.

12. The vector described in claim 11, which is a viral vector.

13. A viral particle comprising the nucleic acid molecule described in claim 1.

14. A pharmaceutical composition comprising the nucleic acid molecule of claim 1 and an excipient.

15. A pharmaceutical composition for treating a genetic disease, comprising the nucleic acid molecule described in claim 1.

16. 16. The pharmaceutical composition of claim 15, wherein the disease is SYNGAP1 encephalopathy, CDKL5 deficiency disorder, STXBP1 encephalopathy, early infantile epileptic encephalopathy type 2, Wilson's disease, early infantile epileptic encephalopathy type 4, mental retardation autosomal dominant 5, aphasia, Alagille syndrome 1, epilepsy, tuberous sclerosis complex-2, tuberous sclerosis complex-1, KIF1A-associated neurological disorder, encephalopathy, Phelan-McDermid syndrome, Becker muscular dystrophy, RP1, retinitis pigmentosa 1, dilated cardiomyopathy 1G, DYNC1H1 syndrome, TRIO-associated intellectual disability (ID), USP9X developmental disorder, progressive myoclonus epilepsy 1 (EPM1), or hyperphenylalaninemia BH4 deficiency D (HPABH4D).

17. a. the target cytosolic protein is SYNGAP1 and the disease is SYNGAP1 encephalopathy; b. the target cytosolic protein is SYNGAP1 and the disease is mental retardation autosomal dominant 5; c. the target cytosolic protein is CDKL5 and the disease is a CDKL5 deficiency disorder; d. the target cytosolic protein is CDKL5 and the disease is early infantile epileptic encephalopathy; e. the target cytosolic protein is CDKL5 and the disease is early infantile epileptic encephalopathy type 2; f. the target cytosolic protein is ATP7B and the disease is Wilson's disease; g. the target cytosolic protein is STXBP1 and the disease is STXBP1 encephalopathy; h. the target cytosolic protein is STXBP1 and the disease is early infantile epileptic encephalopathy; i. the target cytosolic protein is STXBP1 and the disease is early infantile epileptic encephalopathy type 4; j. The target cytosolic protein is GRN and the disease is primary progressive aphasia and FTD (frontotemporal degeneration); k. the target cytosolic protein is JAG1 and the disease is Alagille Syndrome 1; l. The target cytosolic protein is DEPDC5 and the disease is epilepsy (e.g., familial focal 1 showing multiple foci); m. the target cytosolic protein is TSC2 and the disease is tuberous sclerosis; n. the target cytosolic protein is TSC2 and the disease is tuberous sclerosis type 2; o. the target cytosolic protein is TSC2 and the disease is tuberous sclerosis type 1; p. the target cytosolic protein is TSC1 and the disease is tuberous sclerosis; q. the target cytosolic protein is TSC1 and the disease is tuberous sclerosis type 1; r. the target cytosolic protein is TSC1 and the disease is tuberous sclerosis type 2; s. the target cytosolic protein is KIF1A and the disease is a KIF1A-associated neurological disorder; t. the target cytosolic protein is DNM1 and the disease is DNM1 encephalopathy; u. the target cytosolic protein is DNM1 and the disease is encephalopathy; v. the target cytosolic protein is SHANK3 and the disease is Phelan-McDermid syndrome; w. the target cytosolic protein is DMD and the disease is Becker muscular dystrophy; x. the target cytosolic protein is RP1 and the disease is retinitis pigmentosa 1; y. the target cytosolic protein is TTN and the disease is dilated cardiomyopathy 1G; z. the target cytosolic protein is DYNC1H1 and the disease is DYNC1H1 syndrome; aa. The target cytosolic protein is TRIO and the disease is TRIO-associated intellectual disability (ID); bb. the target cytosolic protein is USP9X and the disease is a USP9X developmental disorder; cc. the target cytosolic protein is CSTB and the disease is progressive epilepsy with myoclonus 1 (EPM1); or dd. The target cytosolic protein is PCBD1 and the disease is BH4-deficient hyperphenylalaninemia D (HPABH4D); 16. The pharmaceutical composition of claim 15.

18. The pharmaceutical composition according to any one of claims 47 to 55, wherein the disease is a haploinsufficiency disease.